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CHAPTER ONE 
INTRODUCTION 
Inflammatory bowel diseases (IBD) affect a large number of individuals around the 
world. This group of diseases is largely composed of two types: Chron’s disease (CD) and 
ulcerative colitis (UC). CD and UC are characterized by inflammation that can occur anywhere 
in the gastrointestinal tract or the colon, respectively. The immediate cause of these diseases is 
not defined but research implicates a combination of genetics, the environment, and the intestinal 
microbiome. Upon development of IBD, patients experience cyclical episodes of inflammation, 
known as flares. Just like the etiology of IBD, flare induction appears to arise from multiple 
factors, which can also vary on a person-to-person basis. Since no cure is available, current 
treatments are aimed at alleviating symptoms and limiting flares in the disease. Commonly, after 
careful observation, components of one’s diet may be recognized as flare inducing, which leads 
to avoidance of that food in the future. One food that physicians frequently recommend that IBD 
patients avoid is alcohol, despite our limited understanding of the mechanism by which alcohol 
affects IBD. 
Alcohol consumption is ubiquitous in today’s society. Whether consumed moderately or 
chronically and in small or large amounts, alcohol can induce a variety of physiological effects 
that have direct implications on an individual’s health. Many of these involve changes in the 
major organ of alcohol metabolism, the liver, like fat deposition and fibrosis which can 
eventually progress to cancer. In addition, alcohol consumption has been linked to a variety of 
malignancies in the upper and lower gastrointestinal tract. Of particular importance is how 
alcohol modifies the intestinal environment, by inducing gut leakiness, altering intestinal 
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microbial populations, and producing reactive substances. These changes induced by alcohol 
consumption parallel many of the changes seen during the active disease state of IBD. Therefore, 
we can anticipate that the combination of alcohol use in the setting of IBD can further exacerbate 
the disease or promote induction of flare. To that end, studies have identified that alcohol use can 
induce gastrointestinal symptoms or flare in IBD patients, however, how these changes occur are 
not defined. A mechanistic understanding of these changes would contribute to the pressing need 
to better understand the effects of alcohol in IBD, while providing targetable pathways to prevent 
IBD flare or limit its severity. Furthermore, this would be especially important in those who 
develop IBD with a concurrent alcohol use disorder, since their ability to limit alcohol 
consumption may be severely impaired and thus require therapies that may work despite their 
continued consumption of alcohol.  
One possibility through which alcohol can affect IBD is via the changes in the intestinal 
microbiome, specifically increases in proinflammatory bacteria and decreases in beneficial 
bacteria. The proinflammatory bacteria can express higher amounts of endotoxin and invade into 
the mucosa. Furthermore, their consumption of nutrients in the nutrient-limited environment of 
the intestine prevents growth of beneficial bacteria and their metabolites key to intestinal health. 
The beneficial bacteria also express lower levels of endotoxin, promote intestinal tight junction 
integrity, and can also inhibit growth of the pro-inflammatory bacteria. Thus, once the 
proinflammatory bacteria establish themselves, they may be active participants in the disease 
cycling of IBD. 
Based on this information, my central hypothesis is that alcohol enhances the symptoms 
associated with colitis by altering intestinal bacterial populations. To address this hypothesis, we 
constructed four aims. Aim 1 determines whether alcohol use affects clinical outcomes of 
patients admitted for IBD, UC, and CD. Aim 2 examines whether there is bacterial dysbiosis 
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after alcohol and DSS treatment and how this alteration occurs. Aim 3 assesses the contribution 
of nitric oxide synthase 2 and nitrate utilization in relation to bacterial and pathologic changes 
observed in the colitis and ethanol model. Aim 4 examines the effects of combined DSS and 
alcohol administration on the liver. 
Various methods were employed to ascertain alcohol’s effects on the intestinal 
microbiome in the setting of colitis. We first used a patient database to determine clinical, 
diagnostic, and therapeutic outcomes of patients admitted for IBD that had a history of alcohol 
use compared to patients admitted for IBD without a history of alcohol use. Previously, our lab 
identified that alcohol can exacerbate a flare period in a mouse model of colitis, which we used 
in the subsequent studies. Cecal and fecal pellets were collected from mice, processed for DNA, 
then assessed for bacteria by quantitative polymerase chain reaction (qPCR). Mucin staining and 
fluorescent in situ hybridization were used to characterize the mucin barrier and bacterial 
infiltration of the mucosa. Isolated intestinal epithelial cells (IECs) were examined for tight 
junction, mucin, bacterial pathogen associated molecular pattern receptors, and antimicrobial 
peptide expression via qPCR. IEC expression of reactive oxygen producing enzymes and Nos2 
was evaluated, with additional examination of Nos2 protein levels by Western blot and 
immunohistochemistry (IHC). Tungstate (W) and L-N6-(1-Iminoethyl)-lysine (L-NIL) treatments 
were given to mice to prevent nitrate utilization and inhibit nitrate production, respectively. 
Global microbiome assessment occurred via 16S rRNA sequencing of DNA isolated from cecal 
contents. Sections of the colon were assessed for histopathology. Livers were examined for cell 
infiltration, fat deposition, inflammatory gene expression, and activation of inflammatory 
signaling pathways.  
Our findings identify that the exacerbated symptoms associated with alcohol in IBD 
patients and our mouse model of colitis may occur by compounding an already perturbed 
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intestinal microbiome, leading to overgrowth of the pro-inflammatory Enterobacteriaceae and 
limiting growth of healthy bacteria like the Lactobacillus. Inhibition of nitrate production and 
nitrate utilization limited Enterobacteriaceae growth in colitis, but when alcohol was 
administered after colitis, the rise in Enterobacteriaceae was only slightly depressed. This 
suggests that nitrate may only partially explain the overgrowth of Enterobacteriaceae when 
alcohol use and colitis are co-occurring. Meanwhile, the liver experiences downregulation of 
inflammatory processes in the combined administration of colitis and alcohol compared to colitis 
alone. The results of these studies have implications for limiting the exacerbation of colitis flares 
and possibly the induction of flare through the promotion of a healthy intestinal microbiome and 
discontinuation of alcohol use.   
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CHAPTER TWO 
REVIEW OF RELATED LITERATURE 
Inflammatory Bowel Disease 
Inflammatory bowel diseases (IBD) are extremely prevalent within the United States, 
affecting 1.5 million individuals, while in other countries the incidence of IBD is increasing 
rapidly(1). The economic burden of IBD patients on the healthcare system is quite high due to 
the lifelong nature of the disease, ineffective treatments, complex therapeutic regimens that are 
difficult to maintain, and the increased likelihood of colorectal cancer development (2-4).There 
are two forms of IBD: Crohn’s disease (CD), which produces discontinuous lesions throughout 
the gastrointestinal tract and ulcerative colitis (UC), which produces a continuous mucosal lesion 
that is localized to the colon. The disease onset of both CD and UC follows a similar course 
whereby patients develop marked changes in bowel habits, often including intense abdominal 
pain, diarrhea, and bloody stools. The diagnosis is often made upon endoscopy and biopsy of the 
intestine, with the combined perspective of the patient’s clinical history. After the initial 
diagnosis, both CD and UC begin a cyclical pattern of disease quiescence and reactivation. The 
etiology of IBD is not known but is thought to be due to a combination of genetic(5-7), 
microbial(8), and environmental/lifestyle factors(9).  
Genetics of Inflammatory Bowel Disease 
Genome wide studies of IBD patients have identified 163 loci associated with the 
disease(7). Of these loci, 110 are associated with both UC and CD, 30 are specific to CD, and 23 
are specific to UC. The genes where these loci are found are quite diverse in their functionality,  
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being involved with immune response, inflammation, mucus formation, intestinal barrier 
integrity, and autophagy, among other functions.  
The most well studied gene in IBD is that of the Nucleotide-binding oligomerization 
domain-containing protein 2 (NOD2). Mutations within NOD2 are strongly correlated with the 
development of CD(5, 10, 11). Normally, NOD2 detects a fragment of bacterial peptidoglycan, 
muramyl dipeptide, leading to downstream activation of the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB)(12). Many of the CD related NOD2 mutations are 
localized to the muramyl dipeptide binding site, a leucine rich repeat domain(10, 11). Cells 
transfected with the NOD2 mutants exhibit decreased immune activation in response to treatment 
with bacteria(11), which appears contrary to the observed increased inflammatory response in 
these patients. However, it is proposed that the loss of function of NOD2 may impose deficits on 
macrophage and/or intestinal epithelial cell recognition of pathogenic bacteria, leading to 
initially dampened immune responses that proceed to persistent infections, which culminate in 
the manifestation of CD(13, 14). For individuals that are homozygous for NOD2 mutations, their 
relative risk of developing CD increases greatly, but possessing these mutations is not sufficient 
for development of CD, suggesting that factors outside genetics are necessary for CD 
development(14, 15). This is strengthened by research examining NOD2 deficient mice, which 
do not develop any overt signs of intestinal inflammation unless a second stimulus is applied(16, 
17). To initiate disease, the NOD2 deficient mice require pretreatment with inflammatory agents 
or reactive T cells, which only then produce disease that is exacerbated relative to wild type 
mice. 
Other mutations implicated in IBD appear to follow a trend similar to that of NOD2 
mutations in that they do not guarantee IBD development but only increase the relative risk. 
Thus, there appears to be non-genetic components that promote the actual manifestation of the 
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disease. One such component that has been thoroughly examined in the context of IBD is the 
intestinal microbiome. 
The Microbiome 
 A microbiome consists of a complex diverse community of organisms, encompassing 
bacteria, fungi, viruses, and bacteriophages. Every multicellular organism is colonized in one 
way or another by a microbiome, be it flies(18), termites(19), whales(20), or plants(21). 
Furthermore, it appears that nearly every anatomical site has its own distinct microbiome(22). 
Human microbiome research has focused on bacteria, particularly those residing within the large 
intestine. Of the roughly 1014 bacteria within the adult human large intestine(23), 2,172 species 
have been identified. Most of the intestinal bacteria fall under five phyla: Firmicutes, 
Bacteroidetes, Proteobacteria, Actinobacteria, and Verrucomicrobia (24-27). In the healthy adult 
human gut, the Firmicutes and Bacteroidetes phyla account for greater than 90% of all bacteria 
(27, 28). These bacteria are capable of encoding 9,879,896 genes(24), about 400 times that of the 
~22,500 human genes(29). In addition, unlike human genes, many of the downstream functions 
of the proteins generated from these bacterial genes remain unknown(30). Moreover, these 
microbiomes are dynamic, exhibiting rhythmic changes that mimic our own biological 
cycles(31). Initially, these microbiomes were largely considered to be commensal and possibly 
even parasitic, but our current understanding indicates that more so than not, the relationship 
between a host and its microbiome is symbiotic. In fact, many times over, researchers have 
shown that microbiomes are essential to health and development. 
The Developing Intestinal Microbiome 
Immediately after birth, human bodies are exposed to a variety of microbial organisms, 
with the intestine being a primary site of this interaction. During the first three years of life, there 
are dynamic fluctuations in the species of bacteria that colonize the intestine, after which the 
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microbial community begins to exhibit a stability, diversity, and relative abundance similar to 
that of the adult intestinal flora(32, 33). The early shifts in the infant intestinal microbiome can 
be related to the infant intestinal nutrient profile, which promotes or inhibits the growth of 
certain bacteria depending on their metabolic capacities. 
Compared to the adult microbiome, the newborn microbiome is characterized by a high 
proportion of Proteobacteria and Actinobacteria, and a lower proportion of  Firmicutes and 
Bacteroidetes(34). The oxygen rich environment promotes the growth of Proteobacteria which 
can proficiently use oxygen as an energy source and also withstand the oxidative effects of 
oxygenated environments. As the oxygen is consumed, Proteobacterial oxidative 
phosphorylation decreases, necessitating a shift to less energetically favorable metabolic 
pathways, like fermentation. Furthermore, compared to other intestinal bacteria, the 
Proteobacteria are less efficient fermenters putting them at a competitive disadvantage(35). With 
the decreased oxygen concentration and the advantage of efficient fermentation pathways, the 
largely oxygen intolerant Firmicutes and Bacteroidetes begin to increase in number. The 
importance of oxygen depletion in allowing growth of obligate anaerobes has been observed in 
germ free mice where colonization of anaerobic bacteria was only achieved by a select group of 
obligate anaerobes(36) or by co-administration with E. coli(37). Importantly, beside bacterial 
consumption, other processes, like endogenous lipid oxidation, appear to play a role in intestinal 
oxygen depletion, since adult germ free mice have the same partial pressure of oxygen within 
their intestines as conventional adult mice(38). 
Infant intestinal Actinobacteria, Bifidobacteria in particular, are heavily linked to a 
vaginal birth and breastfeeding(39). Specifically, there is direct vertical transmission of these 
bacteria from the mother to the infant, as studies have identified the same exact strains of 
Bifidobacteria in infant intestinal contents which are also observed in the mother’s feces(40, 41), 
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breast milk(42), or both the feces and milk(43, 44). In addition, the maintenance of these bacteria 
within the intestine ishighly dependent on breast milk, since it contains complex 
oligosaccharides which the infant cannot break down and are only be utilized by select 
Bifidobacteria(45, 46). Weaning and the introduction of solid foods leads to decreased 
Actinobacteria(47, 48), and an increase in the bacterial diversity(49) which begins to mirror that 
of the adult intestinal microbiome(50, 51).  
During this initial time period of microbiome development, numerous additional factors 
can influence the microbiome. For example, immediately after birth newborns delivered by 
cesarean exhibit intestinal bacteria similar to the mother’s skin microbiome, while those 
delivered vaginally exhibit a microbiome similar to that of the mother’s vagina(51, 52). Cesarean 
section newborns have decreased intestinal Bacteroides and Bifidobacterium; they also exhibit 
an adult-like microbiome sooner than that of vaginal births(50, 53). Interestingly, applying 
vaginal fluid to neonates born by cesarean section can help in promoting their microbiome to 
resemble that of a vaginal birth(54). Other alterations in the developing infant microbiome have 
be attributed to antibiotic use(33) and formula feeding versus breast feeding (33, 50). It should 
be noted, the trajectories of bacterial changes in a developing infant are not absolute, with 
numerous studies showing variation, some of which may be attributed to the methods used and 
selected study population (34, 49-51, 55). Furthermore, we lack the understanding of how or 
even if the early intestinal microbiome changes can produce long lasting effects on the infants 
later in life. Despite this, there is a clear role in health that the intestinal microbiota plays, since 
animals that develop in the absence of any microbial interaction, identified as germ-free(GF) or 
gnotobiotic exhibit deficiencies in variety of  health and physiological parameters(56). 
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Intestinal Microbiome and Immune System Development 
GF animals were noted to have profound histologic and morphologic differences in their 
small intestine compared to conventionally raised animals. In the GF mice, the small intestine 
villi appear more uniform, the crypts are not as deep, and there is decreased turnover of epithelial 
cells(57). From an immunological perspective, the lamina propria and the mucus layer are 
thinner(37, 57, 58). The thinned lamina propria, which contains the bulk of intestinal immune 
cells that normally sample the luminal environment of the intestine, is due to decreased immune 
cell number and activity(57, 59). Furthermore, the decreased presence and activation of immune 
cells coincides with depressed levels of circulating serum immunoglobulin, meanwhile, this 
dampened immune response can be rescued by the inoculation of bacteria(58, 59). The various 
products of the bacteria, like their surface molecules, lipopolysaccharide (LPS) and muramyl 
dipeptide, and their metabolites, like short chain fatty acids (SCFAs), are key in promoting the 
proper development of the systemic and intestinal immune system. 
Intestinal Microbiome Metabolite Production 
Studies have identified that microbiome also plays a major role in host metabolism. 
When the microbiome is absent such as in GF animals, metabolism and nutrient absorption are 
severely disrupted. For example, compared to conventional mice, GF mice have decreased 
circulating levels of vitamin D(60) and become more moribund when administered vitamin 
deficient diets(61, 62). In addition, GF mice are susceptible to Vitamin K deficiency, because a 
portion of Vitamin K is derived from intestinal bacterial metabolism(63-65). This same 
deficiency can even manifest in humans after taking broad spectrum antibiotics(66). Bacteria are 
capable of synthesizing a wide array of vitamins and metabolites(67), which some researchers 
are beginning to explore in a probiotic context. For example, studies have identified that 
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administration of folate synthesizing bacteria, are capable of increasing concentrations of folate 
in the feces(68) and in the serum(69).  
One group of essential bacterial metabolites is the SCFAs, which are the product of 
bacterial fermentation derived from dietary fibers. The SCFAs are widely recognized as 
important for the maintenance of intestinal health and health of the host. When the microbiome is 
absent, the cecum of mice greatly expanded as a result of accumulated mucin and dietary 
fibers(70), which is associated with SCFA depletion(71). The intestinal SCFAs are largely 
composed of butyrate, propionate, acetate. Butyrate is of particular importance within the 
intestine, as it produces a variety of signaling and metabolic effects, most of them localized 
directly to the intestine. Butyrate is the preferred energy source for intestinal epithelial cells(72-
74), and nearly all of the intestinal butyrate is absorbed by these cells. In the intestines of GF 
mice, where bacterial production of butyrate is absent, there is selective deprivation of energy 
limited to the colonocytes, which can be rescued by the administration of butyrate producing 
bacteria(75). Aside from its role as an energy source, upon entering certain cell types, butyrate 
can act also act as a histone deacetylase inhibitor(76, 77) and promote the induction of T 
regulatory cells(78). Butyrate can also exert its effect through activation of G-protein coupled 
receptors, which produce intracellular signaling that regulate fatty acid and glucose 
metabolism(79). On its own, butyrate has been implicated in a variety of defense mechanisms by 
increasing production of intestinal mucins (80-82) increasing antimicrobial peptide 
production(83), and inhibiting the upregulation of pathogenicity islands in Salmonella(84).  
Numerous bacteria are capable of producing butyrate directly (Prevotellaceae, 
Clostridiaceae, Ruminococcaceae, and Lactobacillaceae) but there are also large numbers of 
bacteria that promote production of butyrate indirectly via cross feeding of substrates, like 
acetate (Ruminococcaceae and Actinomycetaceae), lactate 
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(Ruminococcaceae and Lactobacillaceae), and succinate (Actinomycetaceae), which other 
bacteria can convert to butyrate(85, 86). While most of butyrate is consumed by the colonic 
mucosa(87), the bulk of intestinally derived acetate and propionate enter the portal venous 
system and where they are eventually absorbed by the liver for use as an energy source or as 
substrates for synthesis of other molecules(79).  
Intestinal Host Defense Mediated by the Microbiome 
A healthy intestinal flora can act to prevent intestinal infection by way of niche 
occupation. This can be understood in the context of Clostridum difficle, a toxin producing 
bacterium that can manifest devastating disease when microbiomes are disrupted. This bacterium 
exists as either a spore, where it is inactive, or as a vegetative bacterium, where it is active and 
produces disease. Around 3% of adult humans carry this pathogen in their intestines, yet very 
few exhibit any symptoms of disease(88). The colonization and manifestation of disease in GF 
animals proceeds unimpeded, due to the lack of a microbiome(89), however, the presence of an 
intestinal microbiome readily suppresses C. difficile growth and disease(90). When antibiotics 
are administered, the spores of C. difficile have an opportunity to geminate and cause disease. 
While possibly being effective in removing bacteria responsible for the underlying infection, the 
antibiotics also non-selectively eliminate healthy bacteria and their metabolic capacities, one of 
which is the transformation of bile acid(91). Animal studies have identified that antibiotics can 
lead to an increases in intestinal primary bile acids, like taurocholate, among other metabolites, 
which promote the germination of C. difficile spores(92, 93). To clear the C. difficile infection, 
the antibiotics metronidazole and/or vancomycin are typically given, but their non-selective 
nature also limits the reestablishment of the healthy intestinal flora, which may account for the 
high recurrence of C. difficile, around 15-30%(94). In these cases, a fecal microbial transplant 
(FMT), sourced from the feces of a healthy human donor and administered as a pill or via 
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endoscopy, is often the next step of treatment. This treatment leads to cures in roughly 90% of 
cases(95, 96). Furthermore, in a study of patients with recurrent C. difficile infection treated with 
FMT, 11 of 12 patients exhibited clinical recovery which was associated with an increase in the 
diversity of the intestinal microbiome and decrease in the intestinal concentrations of primary 
bile acids(97). 
Similar niche occupation is seen in mouse models of Salmonella infection, where bacteria 
from the Enterobacteriaceae family, which includes the Salmonella genus, impede infection 
unless extremely high doses of Salmonella are administered(98). This may be explained in part 
by the consumption of oxygen and other electron acceptors by the endogenous 
Enterobacteriaceae(99-101).  
 Co-culturing of bacteria to identify their potential to inhibit the growth of other bacteria 
has also provided some insight into maintenance of a healthy intestinal microbiome. Lactobacilli 
are a generally safe genus of bacteria, often used probiotics, and have been utilized in a variety 
of settings to ameliorate intestinal diseases. Various studies have examined its co-culture with 
pathogenic bacteria or Enterobacteriaceae and have largely found that the Lactobacillus can exert 
anti-proliferative effects on these bacteria(102-106). The ability by which Lactobacillus 
accomplishes this is thought to occur by production of SCFAs and lactic acid that alter the pH of 
the culture, which the Lactobacillus can tolerate but the other bacteria cannot(107).   
Defense against invading organisms can also be accomplished by the maintenance of 
acidic intestinal pH and the production of SCFAs. Neither of which are mutually exclusive. An 
optimal pH promotes SCFA production from SCFA-producing bacteria while also favoring their 
growth, and then the SCFAs themselves influence intestinal pH because they are mildly 
acidic(79, 108). As would be expected a strong correlation exists between lower pH and high 
SCFA concentrations in the intestine(87). Culturing of intestinal contents with varied pHs 
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demonstrated that, butyrate production is particularly favored at lower pH (~5.5), while actetate 
and propionate are favored at slightly higher pH (~6.5)(109). Numerous studies have identified 
that lower pHs, increased SCFAs, or both can inhibit the growth of Enterobacteriaceae (110-
112).  
Microbiome in IBD 
In the setting of IBD, an intestinal dysbiosis is observed, wherein the intestinal bacterial 
communities are altered relative to healthy individuals. The IBD dysbiosis is characterized by 
marked increases in the Proteobacteria phyla(113-115), which are normally maintained at low 
levels in the intestine(27), and decreases in bacteria from the Firmicutes and Bacteroidetes 
phyla(116). The increase in Proteobacteria is most often due to an expansion of bacteria from the 
Enterobacteriaceae family, which is composed of gram negative facultative anaerobic 
bacilli(117). Whether these bacteria instigate, participate, or are a mere consequence of the 
disease process of IBD is not entirely defined. 
Various studies examining mice with NOD2 deficiency, identified alterations in the 
intestinal microbiota(16, 118-120), increased susceptibility to bacterial infection(121), or 
both(122). However, transplantation of the intestinal microbiota from NOD2 deficient mice to 
healthy mice gave mixed results, with one study showing that colitis and colorectal cancer were 
transmissible(118), while another study did not reproduce this finding(16). In a separate study, 
no difference in relative abundance of various intestinal bacteria was observed in NOD2-
deficient mice(123). In humans with IBD, NOD2 mutations exhibit a positive correlation 
between intestinal Enterobacteriaceae load and the pressence of one or more NOD2 mutations, 
although this occurs irrespective of whether the patient has CD or UC(124).  
As mentioned earlier, butyrate is an essential energy source for colonocytes, and thus 
changes in intestinal butyrate concentration can lead to a dysfunctional shift in colonocyte 
 15 
metabolism. Such a change is observed in UC patient colonocytes, which utilize less butyrate 
than colonocytes from control patients, with the energy deficit being compensated by the 
utilization of glucose(125). Similar effects on colonocyte butyrate utilization are observed in 
colonocytes isolated from a mouse model of colitis(126). Furthermore, antibiotic treatment that 
eliminates butyrate producing bacteria, promotes Enterobacteriaceae overgrowth in part due to 
increased luminal oxygen concentrations that would normally be used by the intestinal 
epithelium to oxidize butyrate(127). In the healthy colon, butyrate utilization is highly favored in 
the distal colon portion compared to the proximal portion(74). This has led to the hypothesis that, 
at least in UC, which manifests initially at the rectum and proceeds proximally, the more distal 
portion of the intestine may be energy starved(125). Due to this, the distal portion of the colon 
cannot maintain its integrity, leading to inflammation and disease. Furthermore, treatments to 
increase intestinal butyrate, directly via enema(128) or indirectly, by either administering 
butyrate producing bacteria(129, 130) or increasing consumption of fibers that enhance bacterial 
production of butyrate(131), have produced some favorable outcomes in murine models of IBD 
and IBD patients.  
Apart from the noted increase in Enterobacteriaceae during colitis, there are noted 
reductions in beneficial bacteria, such as Lactobacillus, which has been observed in UC 
patients(132). Thus, researchers have attempted to reintroduce these bacteria, which has largely 
been met with favorable outcomes(133-135). Furthermore, the probiotic VSL#3, which has been 
used to successfully maintain UC patients in remission(136) and even promote entrance into 
remission from active UC(137), actually contains four different strains of Lactobacillus, among 
strains of Bifidobacteria  and Stretptococcus. 
Aside from identifying differences in individual bacteria, assessment of the overall 
bacterial diversity revealed that IBD patients have a decreased diversity relative to healthy 
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controls(138). Efforts to reestablish diversity through fecal microbial transplant (FMT) have 
been somewhat promising. Changes in bacterial diversity and UC remission are limited when 
administering a single transplant from a single donor.(139, 140). In contrast, trials that utilized 
multiple transplant administrations(141, 142) or fecal samples from multiple donors(143) had 
greater success in increasing microbial diversity and achieving UC remission. These recent 
findings highlight the significant role played by the intestinal microbiota in UC and how their 
normalization is important.   
Altered Nutrient and Redox Profile in the Intestines of IBD Patients 
As described earlier, the nutrients within the large intestine are a major driving force for 
the selective increase in some bacteria over others. In the healthy large intestine, fermentation of 
indigestible polysaccharides is the primary source of ATP generation(144). Due to their 
fermentation efficiency, the Bacteroidetes and Firmicutes phyla dominate the large intestine(27, 
28, 35). During flares of UC, inflammation leads to the production of free radicals mostly 
derived from oxygen (i.e. superoxide anion, hydrogen peroxide, hydroxyl radical)(145, 146) and 
nitrogen (i.e. nitric oxide, peroxynitrite)(147). These free radicals are produced by colonocytes 
and invading immune cells with a primary purpose of killing bacteria that are invading into the 
epithelium and surrounding tissue. The large proportion of intestinal bacteria that come into 
contact with the free radical burst will be neutralized as the radicals induce oxidation of lipids, 
proteins, and DNA(148). However, some bacteria, like the Enterobacteriaceae, have the ability to 
detoxify these radicals, using enzymes like superoxide dismutase, peroxidase, catalase, and 
cytochrome bd oxidase(149, 150). The Enterobacteriaceae also express siderophores that can 
inhibit ROS production, which can also enhance Enterobacteriaceae virulence(151-153).  
In addition, the Enterobacteriaceae are capable of using downstream products of 
inflammation as substrates for ATP generation(154). One of these substrates include nitrate, 
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which is increased during an active UC flare(147). Enterobacteriaceae, can utilize nitrates as the 
terminal electron acceptor during the process of anaerobic respiration(155), while the  
Bacteroidetes and Firmicutes cannot or are extremely inefficient(156). Furthermore, the 
reduction of nitrate during anaerobic respiration and oxygen during oxidative phosphorylation is 
much more energetically favorable than polysaccharide fermentation(155), and thus may allow 
for the observed overgrowth of Enterobacteriaceae(157).  
The intestinal inflammation during IBD flare may also affect the pathogenicity and 
fitness of Enterobacteriaceae, as inflammation promotes horizontal gene transfer between 
Enterobacteriaceae(158). Furthermore, in both UC and CD, select variants of Escherichia coli 
are increased relative controls(159), particularly those with enteroadhesive properties(160). 
The alteration in the oxidative potential within the intestine during IBD has been 
proposed to play a role in the dysbiosis of the intestine(161). This hypothesis is based on the 
decrease of viable obligate anaerobes and the overgrowth of facultative anaerobes and aerobes in 
the intestines of IBD patients. This could account for the decreased diversity in IBD intestinal 
bacteria. Furthermore, when UC patients enter into a remission period their intestines exhibit 
increases in the obligate anaerobe and butyrate producer Faecalibacterium prausnitzii(162, 163). 
This study also found that UC patients who eventually had a relapse were likely to have a 
decreased abundance of this bacterium(162). 
 The change in intestinal oxygenation could also lead to a shift in the mutualism of 
bacteria. In the healthy intestine, a cross-talk exists between the bacterial communities in which 
there is cross-feeding of metabolites, where bacterial fermentation of one substrate leads to the 
formation of a product that is utilized as substrate for energy by another bacterium, such as the 
conversion of acetate to butyrate(164). In an in vitro system, researchers modeled bacterial 
interactions through co-culture under anoxic or normoxic conditions. Surprisingly, bacteria that 
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were normally mutualistic in an anoxic environment, became parasitic in a normoxic 
environment(165).  
Mucus Defects in IBD 
In the healthy large intestine, epithelial cell interaction with the bacterial populations is 
buffered by a coating of mucus. The mucus is composed of two layers. The first layer is 
normally nonpermeable and lies immediately adjancent to the intestinal epithelial cells. The 
second layer is considered semipermeable and resides between the first layer and the lumen of 
the intestine(166). Intestinal bacteria can be classified based on their localization to this mucus. 
The Firmicutes reside further from the mucus in the lumen of the intestine, while the 
Proteobacteria are enriched in the semipermeable mucus layer(167, 168). This distribution is 
likley related to the preferred habitat of these organisms, where the Firmicutes grow optimally in 
the anoxic environment of the lumen while the Protebacteria prefer growth near the slighlthy 
more oxygenated mucosal tissue, which allows them to use oxygen that has diffused from the 
bloodsteam into the mucus. 
Changes in the intesitnal mucus barrier of IBD patients, particularly those with UC, leads 
to a differential distribution of the intestinal micorbiota. In UC a variety of deleterious changes 
occur to the mucus layer, like decreased thickness(169), altered composition(170, 171), and 
decreased mucin producing goblet cells(172). Exhausiton of the goblet cells, as measuered by a 
decreased release of mucin in response to a bacterial ligand, has also been observed in biospies 
from patients with active UC(171). These changes in the mucus layer allow for increased 
interaction of bacteria with the epithelium, which can lead to an inflammatry response. The 
Enterobacteriaceae are known to penetrate the mucus layer of UC patient intestines(113, 114, 
173) and studies carried out in UC disease models show that the bacterial penetration of the 
mucus layer occurs before the onset of intestinal tissue damage(174, 175). Even during UC 
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remission, bacteria can still be localized to the intestinal epithelium as well as the lamina 
propria(173). This may be explained by these patients having increases in the semipermeable 
mucus layer compared to healthy controls and deficeits in the chloride-bicarbonate exchanger, 
SLC26A3, which is important for proper mucin secertion(171).  
Current Understanding of IBD and Alcohol 
Upon development of IBD, individuals experience cyclical periods of disease remission 
and reactivation. The triggers of reactivation appear to be multifactorial but can be precipitated 
by certain foods (176). Though physicians caution IBD patients against alcohol consumption, 
sparse and conflicting studies have been published on the topic. Focusing specifically on UC, 
studies have shown that alcohol can affect reactivation (177, 178). However, the few studies 
examining the effects of alcohol use on UC onset have been inconsistent with studies showing 
positive correlation (179), negative correlation(180), or no correlation(181). Thus, our 
understanding of alcohol’s ultimate effects in this disease remains unclear.  
On its own, alcohol intake, particularly the binge drinking variety, imposes a heavy 
burden on society. According to a 2015 survey of United States individuals 18 and older, 56% 
reported drinking in the past month(182), and 26.9% reported binge drinking in the past 
month(183). Economically, misuse of alcohol has cost nearly 249 billion dollars(184). Based on 
its societal impact, it’s important to understand how alcohol may be contributing to the disease 
state of IBD. Use of alcohol has been associated with altered metabolism(185), immune 
function(186), gut barrier integrity(187, 188), and an intestinal dysbiosis (189-192), which 
exhibits a similarity to that of the dysbiosis in observed in UC(115, 193). 
Effects of Alcohol on the Intestinal Microbiome 
Individuals with chronic overconsumption of alcohol are noted to have increased 
Enterobacteriaceae populations(194, 195). The changes related to Lactobacillus are less clear, as 
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studies have identified alcoholics as having decreased intestinal Lactobacillus(195), while others 
identify increased intestinal Lactobacillus(194). Methodological differences in determining 
Lactobacillus may account for some of these changes, as the former study used quantification of 
live bacterial colonies and the latter used sequencing. Studies of the oral microbiome identified 
that compared to non-drinkers, moderate alcohol consumers display increased 
Enterobacteriaceae and decreased Lactobacillus, which is more pronounced in heavy 
drinkers(196). Despite these differential changes in Lactobacillus, administration of 
Lactobacillus in the individuals with alcohol use and models of alcohol consumption are broadly 
beneficial(191, 195, 197, 198). 
Similar to humans, alcohol intake in murine models can cause perturbations of the 
intestinal microbiome with increases in Proteobacteria/Enterobacteriaceae(191, 199, 200). 
However, just as in humans, the proportion of Lactobacillus can either increase(199) or decrease 
in such models(200, 201). 
After alcohol intake, the concentration of alcohol observed in the bloodstream mirrors 
that seen along the lower gastrointestinal(202), while the alcohol metabolite, acetaldehyde, is 
produced in appreciable amounts within the intestine(203, 204). This increase in acetaldehyde is 
attributed to metabolism that occurs by the IECs and the intestinal bacteria(203, 204). 
Furthermore, treatment with metronidazole, boosts intestinal acetaldehyde concentrations, which 
is attributed to a decrease of intestinal anaerobic bacteria and increase in aerobic bacteria, 
particularly the Enterobacteriaceae(204). Meanwhile, the metronidazole treatment does not 
induce any effect on blood levels of ethanol(204). Select strains of intestinally derived E. coli are 
able to oxidize ethanol to acetaldehyde under conditions similar to that found within the 
intestine(205).  
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The relevance of having increased intestinal acetaldehyde concentrations derives from its 
reactive nature (206, 207), which is implicated in cancer(208, 209), and its ability to disrupt 
intestinal tight junctions(210-212) leading to intestinal permeability(197). In addition, a single 
binge of alcohol(197) or chronic administration(213), can produce decreased expression of tight 
junction proteins which likely contribute to the increased permeability. The increased 
permeability leads to increased circulating endotoxin which is eventually trafficked to the liver 
inducing inflammation(197, 214).  
 Alcohol also influences handling of iron, a limiting micronutrient essential for bacterial 
growth. Consumption of alcohol downregulates expression of hepcidin, which normally 
functions to inhibit intestinal iron absorption or inhibit release of iron stored in macrophages, and 
therefore increases circulating levels of iron(215). In a study, individuals consuming more than 
two alcoholic drinks a day were found to be at significant risk of iron overload(216). These 
changes in iron are relevant to the Enterobacteriaceae since they express siderophores with a 
high affinity for iron, while numerous studies have shown that additional iron enhances the 
virulence of the Enterobacteriaceae(217). 
Conclusions 
 A variety of mechanisms appear to play a role in pathogenesis of IBD flare and onset, 
with particular influences derived from the intestinal microbiome. A healthy microbiome 
consists of a complex network of diverse bacteria that directly interface with the intestinal 
mucosa to provide essential nutrients to the epithelial cells and underlying immune cell 
populations. These bacteria also serve in a defensive capacity by preventing the growth or 
colonization of potentially pathogenic bacteria. During IBD flare, there are significant shifts in 
the intestinal bacterial populations with increases in pro-inflammatory bacteria and decreases in 
beneficial bacteria. The infiltrative nature of these pro-inflammatory bacteria and concomitant 
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changes in the intestinal mucosa, such as decreased mucin expression, allows for the direct 
interaction of these bacteria with the intestinal mucosa. In mouse models of colitis, penetration of 
these bacteria precedes the onset of intestinal inflammation. Alcohol consumption leads to 
changes within the intestinal environment that are similar to those observed in IBD, chiefly 
increased pro-inflammatory bacteria and decreased beneficial bacteria, as well as alterations in 
the mucosa, such as tight junction protein disruption. There are tentative associations between 
alcohol consumption and the disease process of IBD, however, how these two factors converge 
in terms of microbial changes has not been defined. First, using a database analysis, we seek to 
expand the clinical effects of alcohol consumption on patients with IBD. Second, using a model 
of ethanol consumption in the setting of colitis developed by our lab, we aim to identify the 
intestinal microbial changes and how they may participate in the exacerbation of a flare period. 
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CHAPTER THREE 
DOCUMENTED HISTORY OF ALCOHOL USE ENHANCES SYMPTOMS AND 
PROPENSITY FOR INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS 
 
Abstract 
 Alcohol consumption is prevalent in the United States and has been linked to the onset 
and exacerbation of numerous diseases. Alcohol has particularly potent effects on the 
gastrointestinal tract related to leakiness, bacterial dysbiosis, and colorectal cancer. However, 
there is a limited understanding of how alcohol can affect the outcomes of patients hospitalized 
for IBD in the context of alcohol use. Due to this, we used inpatient databases from New York 
and Florida to stratify patients into cohorts based on their first admission UC or CD. Studies also 
examined the UC and CD patients as a whole in the IBD cohort. These cohorts were then 
separated based on their history of alcohol use as determined by diagnosis codes. The patients 
were matched for various commodities to isolate the effect of alcohol on IBD. We concluded that 
alcohol negatively impacts patients admitted for IBD leading to increased intestinal infections, 
antibiotic injections, and diagnostic procedures.  
Introduction 
Alcohol consumption can promote inflammation and directly harm the intestinal barrier 
leading to intestinal permeability (192, 218-220). Alcohol induced intestinal permeability, allows 
for increased interaction of luminal bacteria with epithelial cells and the underlying gut 
associated lymphoid tissue. This enhanced interaction leads to activation of the immune system 
while simultaneously releasing bacteria and their products into the bloodstream(200, 220, 221). 
Despite this, only a handful of studies have explored the impact of alcohol in the setting of IBD. 
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In studies of UC patients, those with higher daily alcohol consumption were more likely 
to have a UC flare(178) and those that drank alcohol had worsening of their gastrointestinal 
symptoms(177). In addition, a self-reported survey identified that alcohol use could worsen IBD 
symptoms(222). In terms of onset of disease, one study identified that intoxication by alcohol 
promotes disease onset(179), while another study describes that alcohol has no effect in the onset 
of UC(181). The limited evidence in supporting or contradicting alcohol's role in IBD flares 
and/or onset prompted us first to elucidate whether alcohol is a contributing factor in UC and CD 
research. 
To address this question, we conducted a retrospective analysis of inpatient databases of 
two states (New York and Florida) to assess clinical outcomes of patients admitted with 
diagnoses for IBD, UC, and CD that either have or do not have documented history of alcohol 
use. The results of this analysis suggested that patients with documented history of alcohol use 
have an increased risk of infections as well as require more diagnostic and therapeutic 
procedures. 
Methods 
Data was obtained from the Healthcare Cost and Utilization Project (HCUP) State in 
Patient Databases (SID) for New York and Florida from 2009–2013. Using the International 
Classification of Diseases, Ninth Revision, Clinical Modification, (ICD‐9‐CM) diagnosis codes, 
three study groups were defined: IBD, UC, and CD. All patient admission data was retained if 
the patient had a primary diagnosis of IBD. All of the ICD‐9‐CM codes used in this study can be 
found in Table 1. In addition, we utilized the HCUP cost‐to‐charge ratio files,  
which provide a ratio of the actual cost relative to the total amount charged to insurance for each 
separate hospital. These files are used to estimate the actual cost for individual patient 
admissions. 
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Comorbidities were assigned to patients on the basis of the Agency for Healthcare 
Research and Quality (AHRQ) comorbidity measures. For each individual patient, if the 
presence of a comorbidity was indicated, then the comorbidity was applied to all of that patient's 
admissions. Patients were classified as smokers based on whether any admission contained ICD‐
9‐CM codes for tobacco use disorder or personal history of tobacco use. To evaluate the impact 
of alcohol on outcomes in IBD, patients were identified as having a documented history of 
alcohol use (+A) based on whether any admission contained ICD‐9‐CM codes relating to alcohol 
use or the AHRQ comorbidity measure for alcohol abuse, otherwise the patients were classified 
as not having a documented history of alcohol use (-A). 
Following this, only admissions for which the primary cause was IBD, UC, or CD were 
retained, and all other admissions were excluded. Patients aged 18–90 years of age were included 
for study. Admissions missing data elements for the median household income national quartile 
for patient ZIP code, unique VisitLink patient identifier, age, length of stay, total charges, and 
patient race, were excluded. The -A and +A patients from each respective study group of IBD, 
UC or CD, were propensity score matched 1:1 at their first admission based on age, sex, race, 
Table 1. ICD9 Codes Used to Identify Diagnoses, Patients and Procedures
Admitting diagnosis
IBD 556.0, 556.1, 556.2, 556.3, 556.4, 556.5, 556.6, 556.8, 556.9, 555.0, 555.1, 555.2, 555.9
UC 556.0, 556.1, 556.2, 556.3, 556.4, 556.5, 556.6, 556.8, 556.9
CD 555.0, 555.1, 555.2, 555.9
Patients
Smoker 305.1, V15.82
Documented history of alcohol use 291.81, 291.82, 291.89, 291.9, 303.00, 30.301, 303.02, 303.03, 303.90, 303.91, 303.92, 303.93, 
305.00, 305.01, 305.02, 305.03, V11.3, AHRQ comorbidity measure for alcohol abuse
Secondary diagnoses during admission
Clostridium difficle infection 008.45
Poorly defined intestinal infection 009.0, 009.1, 009.2, 009.3
All other intestinal infections (inclusive of 
C. difficle and poorly defined intestinal 
infection)
008.00, 008.01, 008.02, 008.03, 008.04, 008.09, 008.1, 008.2, 008.3, 008.41, 008.42, 008.43, 
008.44, 008.45, 008.46, 008.47, 008.49, 008.5, 008.61, 008.62, 008.63, 008.64, 008.65, 008.66, 
008.67, 008.69, 008.8, 009.0, 009.1, 009.2, 009.3
Procedures
CT scan of abdomen 88.01
Small intestine biopsy 45.14, 45.15, 45.16, 45.19
Small intestine resection 45.33, 45.61, 45.62, 45.63
Colectomy 45.81, 45.82, 45.83
Large intestine biopsy 45.25, 45.26
Rectal biopsy 48.24, 48.25
Antibiotic injection 99.21
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primary expected payer, median household income national quartile for patient ZIP code, 
smoking status, and various comorbidities (AIDS, congestive heart failure, chronic pulmonary 
disease, coagulopathy, depression, diabetes mellitus, drug abuse, hypertension (combined 
complicated and uncomplicated), neurological disorders, obesity, psychoses, and renal failure). 
Subsequent admissions of propensity matched patients following their first recorded hospital 
admission were collected. The complete admission history of matched patients within each study 
group was used for data analysis, allowing for a 5-year perspective of what occurs when -A and 
+A patients are admitted for IBD, UC, or CD. Patient selection workflow is detailed in Figure 1. 
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Figure 1. Patient Data Collection Workflow. 
 
New York (2009-2013)
Total admissions: 12,801,935 
Florida (2009-2013)
Total admissions: 12,166,880  
Exclude patients without a history of primary diagnosis of IBD12,307,601New York admissions excluded
11,218,604
Florida  admissions excluded
Merge New York and Florida Datasets
Assign comorbidities, smoking status, documented alcohol use to patients
Exclude admissions where IBD is not 
primary cause of admission
1,368,025
Admissions excluded
Exclude patients if age<18 or age>90
Exclude admissions with missing data
7,425
Admissions excluded
Perform propensity matching
Obtain 2,021 matched patients in each 
IBD-A and IBD+A
Total # of admissions for 
IBD-A = 4,965; IBD+A = 4,013 
Assign procedure variables separately for states
Exclude admissions where UC is not 
primary cause of admission
1,414,040 
Admissions excluded
Exclude patients if age<18 or age>90
Exclude admissions with missing data
3,116
Admissions excluded
Perform propensity matching
Obtain 992matched patients in each 
UC-A and UC+A
Total # of admissions for 
UC-A = 1,602; UC+A = 1,437 
Exclude admissions where CD is not 
primary cause of admission
1,396,595 
Admissions excluded
Exclude patients if age<18 or age>90
Exclude admissions with missing data
4,028
Admissions excluded
Perform propensity matching
Obtain 1,083 matched patients in each 
CD-A and CD+A
Total # of admissions for 
CD-A = 3,089; CD+A = 2,548
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Results 
Within the patient database study groups, there were 41,810 IBD patients, 18,695 UC 
patients, and 24,059 CD patients that met the inclusion criteria. The baseline demographics of 
these groups are shown in Tables 2, 3 and 4, respectively. Additional demographics are shown 
in Table 5. Before matching, the age, race, primary expected payer, and median household 
income, were nearly all significantly different between the -A and +A patients, notwithstanding 
the age of patients in the UC study group. Males, African Americans, and smokers were 
overrepresented within the +A patients. With regard to the primary expected payer, the +A 
patients were more likely to carry Medicaid and self‐pay, while being less likely to carry private 
insurance. The lowest quartile for median household income contains more +A patients then -A 
patients, while the inverse can be seen for the highest income quartile. The +A patients had 
significantly increased comorbidities across all measures compared to the -A patients (Table 5). 
 
Table 2. IBD Patient Demographics and Commoribidites Pre and Post Match
Pre match Post match
IBD-A (n=39,730) IBD+A  (n=2,080) p value IBD-A (n=2,021) IBD+A (n=2,021) p value
Mean Age 47.05 48.21 0.0009 48.19 48.3 0.8251
Sex < 0.001 0.948
Male 17,658 (44.4%) 1,343 (64.6%) 1,289 (63.8%) 1,287 (63.7%)
Female 22,072 (55.6%) 737 (35.4%) 732 (36.2%) 734 (36.3%)
Race < 0.001 0.728
White 28,440 (71.6%) 1,435 (69.0%) 1,409 (69.7%) 1,398 (69.2%)
African American 4,112 (10.3%) 315 (15.1%) 302 (14.9%) 303 (15.0%)
Hispanic 4,715 (11.9%) 221 (10.6%) 218 (10.8%) 214 (10.6%)
Asian or Pacific 
Islander 518 (1.3%) 19 (0.9%) 12 (0.6%) 19 (0.9%)
Native American 74 (0.2%) <10 (%)* <10 (%)* <10 (%)*
Other 1,871 (4.7%) 87 (4.2%) 79 (3.9%) 84 (4.2%)
Smoking Status < 0.001 0.139
Non smoker 26,956 (67.8%) 466 (22.4%) 427 (21.1%) 466 (23.1%)
Smoker 12,774 (32.2%) 1,614 (77.6%) 1,594 (78.9%) 1,555 (76.9%)
*AHRQ restricts reporting of values when n<10
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Post propensity matching, the differences observed for age, sex, race, smoker status, 
primary expected payer, median household income, and comorbidities between the -A and +A 
patients within the three study groups were no longer statistically significant (Table 2, 3, 4, 5). 
For the IBD study group, there were 2,021 matched patients (Table 2), that encompassed 4,965 
IBD-A admissions and 4,013 IBD+A admissions (Table 6). For the UC study group, there were 
Table 3. UC Patient Demographics and Commoribidites Pre and Post Match
Pre match Post match
UC-A (n=17,653) UC+A (n=1,042) p value UC-A (n=992) UC+A (n=992) p value
Mean Age 50.48 50.45 0.9519 50.68 50.72 0.9515
Sex < 0.001 0.569
Male 7,712 (43.7%) 706 (67.8%) 649 (65.4%) 661 (66.6%)
Female 9,941 (56.3%) 336 (32.2%) 343 (34.6%) 331 (33.4%)
Race < 0.001 0.698
White 12,039 (68.2%) 665 (63.8%) 647 (65.2%) 636 (64.1%)
African American 1,926 (10.9%) 172 (16.5%) 152 (15.3%) 162 (16.3%)
Hispanic 2,443 (13.8%) 136 (13.1%) 143 (14.4%) 130 (13.1%)
Asian or Pacific 
Islander 293 (1.7%) 11 (1.1%) 10 (1.0%) 11 (1.1%)
Native American 40 (0.2%) <10 (%)* <10 (%)* <10 (%)*
Other 912 (5.2%) 56 (5.4%) 39 (3.9%) 51 (5.1%)
Smoking Status < 0.001 0.502
Non smoker 12,546 (71.1%) 258 (24.8%) 245 (24.7%) 258 (26.0%)
Smoker 5107 (28.9%) 784 (75.2%) 747 (75.3%) 734 (74.0%)
*AHRQ restricts reporting of values when n<10
Table 4. CD Patient Demographics and Commoribidites Pre and Post Match
Pre match Post match
CD-A (n=22,956) CD+A (n=1,103) p value CD-A (n=1,083) CD+A (n=1,083) p value
Mean Age 44.26 45.88 0.0005 45.35 45.82 0.4906
Sex < 0.001 0.826
Male 10,332 (45.0%) 682 (61.8%) 657 (60.7%) 662 (61.1%)
Female 12,624 (55.0%) 421 (38.2%) 426 (39.3%) 421 (38.9%)
Race < 0.001 0.666
White 16,994 (74.0%) 804 (72.9%) 792 (73.1%) 790 (72.9%)
African American 2,298 (10.0%) 163 (14.8%) 166 (15.3%) 159 (14.7%)
Hispanic 2,392 (10.4%) 91 (8.3%) 94 (8.7%) 89 (8.2%)
Asian or Pacific 
Islander 236 (1.0%) <10 (%)* <10 (%)* <10 (%)*
Native American 35 (0.2%) <10 (%)* <10 (%)* <10 (%)*
Other 1,001 (4.4%) 36 (3.3%) 23 (2.1%) 36 (3.3%)
Smoking Status < 0.001 0.664
Non smoker 14,935 (65.1%) 215 (19.5%) 207 (19.1%) 215 (19.9%)
Smoker 8,021 (34.9%) 888 (80.5%) 876 (80.9%) 868 (80.1%)
*AHRQ restricts reporting of values when n<10
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992 matched patients (Table 3), that encompassed 1,602 UC-A admissions and 1,437 UC+A 
admissions (Table 6). For the CD study group, there were 1,083 matched patients (Table 4), that 
encompassed 3,089 CD-A admissions and 2,548 CD+A admissions (Table 6). 
Examination of intestinal infection diagnoses during the admission for either the IBD, 
UC, or CD study groups revealed that +A patients had significantly increased intestinal 
infections (Table 6). The IBD+A patients had increased Clostridium difficile intestinal infection 
(2% vs. 2.6%, p < 0.05), poorly defined intestinal infection (0.4% vs. 0.8%, p < 0.01), and 
overall intestinal infections (2.6% vs. 3.9%, p < 0.01). The UC+A patients had increased poorly 
defined intestinal infections (0.6% vs. 1.5%, p < 0.05), while the CD+A patients had increased 
intestinal infections of all types (2.1% vs. 3.1%, p < 0.05). 
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Table 5. Additional Patient Demographics and Commoribidites Pre and Post Match
Pre match Post match Pre match Post match Pre match Post match
IBD-A 
(n=39,730)
IBD+A 
(n=2,080) p value
IBD-A 
(n=2,021) IBD+A (n=2,021) p value UC-A (n=17,653)
UC+A 
(n=1,042) p value UC-A (n=992) UC+A (n=992) p value
CD-A 
(n=22,956)
CD+A 
(n=1,103) p value
CD-A 
(n=1,083)
CD+A 
(n=1,083) p value
Primary Expected Payer < 0.001 0.863 < 0.001 0.772 < 0.001 0.908
Medicare 10,499 (26.4%) 598 (28.8%) 580 (28.7%) 588 (29.1%) 5,504 (31.2%) 322 (30.9%) 313 (31.6%) 315 (31.8%) 5,188 (22.6%) 298 (27.0%) 284 (26.2%) 295 (27.2%)
Medicaid 5,255 (13.2%) 530 (25.5%) 479 (23.7%) 494 (24.4%) 2,188 (12.4%) 282 (27.1%) 256 (25.8%) 251 (25.3%) 3,257 (14.2%) 267 (24.2%) 256 (23.6%) 254 (23.5%)
Private inusrance 19,324 (48.6%) 524 (25.2%) 548 (27.1%) 524 (25.9%) 7,919 (44.9%) 235 (22.6%) 218 (22.0%) 235 (23.7%) 11,784 (51.3%) 308 (27.9%) 309 (28.5%) 308 (28.4%)
Self-pay 2,754 (6.9%) 262 (12.6%) 265 (13.1%) 255 (12.6%) 1,185 (6.7%) 132 (12.7%) 138 (13.9%) 124 (12.5%) 1,645 (7.2%) 133 (12.1%) 129 (11.9%) 133 (12.3%)
No charge 670 (1.7%) 77 (3.7%) 63 (3.1%) 74 (3.7%) 309 (1.8%) 36 (3.5%) 27 (2.7%) 33 (3.3%) 377 (1.6%) 42 (3.8%) 42 (3.9%) 42 (3.9%)
Other 1,228 (3.1%) 89 (4.3%) 86 (4.3%) 86 (4.3%) 548 (3.1%) 35 (3.4%) 40 (4.0%) 34 (3.4%) 705 (3.1%) 55 (5.0%) 63 (5.8%) 51 (4.7%)
Median household income for patient's 
ZIP Code < 0.001 0.206 < 0.001 0.332 < 0.001 0.98
0-25th percentile 8,832 (22.2%) 665 (32.0%) 606 (30.0%) 632 (31.3%) 4,047 (22.9%) 362 (34.7%) 316 (31.9%) 331 (33.4%) 4,999 (21.8%) 326 (29.6%) 323 (29.8%) 318 (29.4%)
26th to 50th percentile (median) 10,065 (25.3%) 580 (27.9%) 613 (30.3%) 568 (28.1%) 4,383 (24.8%) 266 (25.5%) 257 (25.9%) 260 (26.2%) 5,904 (25.7%) 334 (30.3%) 327 (30.2%) 325 (30.0%)
51st to 75th percentile 10,131 (25.5%) 460 (22.1%) 472 (23.4%) 454 (22.5%) 4,544 (25.7%) 212 (20.3%) 239 (24.1%) 206 (20.8%) 5,812 (25.3%) 260 (23.6%) 258 (23.8%) 258 (23.8%)
76th to 100th percentile 10,702 (26.9%) 375 (18.0%) 330 (16.3%) 367 (18.2%) 4,680 (26.5%) 202 (19.4%) 180 (18.1%) 195 (19.7%) 6,241 (27.2%) 183 (16.6%) 175 (16.2%) 182 (16.8%)
Comorbidities
AIDS 103 (0.3%) 19 (0.9%) < 0.001 15 (0.7%) 18 (0.9%) 0.6 67 (0.4%) 17 (1.6%) < 0.001 <10 (%)* <10 (%)* 0.502 39 (0.2%) <10 (%)* < 0.001 <10 (%)* <10 (%)* 0.654
Congestive heart failure 2,399 (6.0%) 246 (11.8%) < 0.001 225 (11.1%) 235 (11.6%) 0.62 1,415 (8.0%) 140 (13.4%) < 0.001 123 (12.4%) 132 (13.3%) 0.546 1,040 (4.5%) 113 (10.2%) < 0.001 101 (9.3%) 106 (9.8%) 0.715
Chronic Pulmonary Disease 7,326 (18.4%) 770 (37.0%) < 0.001 755 (37.4%) 733 (36.3%) 0.473 3,500 (19.8%) 395 (37.9%) < 0.001 358 (36.1%) 368 (37.1%) 0.641 4,039 (17.6%) 403 (36.5%) < 0.001 403 (37.2%) 386 (35.6%) 0.448
Coagulopathy 2,882 (7.3%) 487 (23.4%) < 0.001 435 (21.5%) 435 (21.5%) 1 1,514 (8.6%) 299 (28.7%) < 0.001 266 (26.8%) 252 (25.4%) 0.474 1,485 (6.5%) 204 (18.5%) < 0.001 186 (17.2%) 190 (17.5%) 0.82
Depression 7,870 (19.8%) 936 (45.0%) < 0.001 863 (42.7%) 884 (43.7%) 0.505 3,476 (19.7%) 452 (43.4%) < 0.001 414 (41.7%) 411 (41.4%) 0.891 4,702 (20.5%) 524 (47.5%) < 0.001 511 (47.2%) 507 (46.8%) 0.863
Diabettus mellitus 5,542 (13.9%) 434 (20.9%) < 0.001 382 (18.9%) 415 (20.5%) 0.192 3,092 (17.5%) 259 (24.9%) < 0.001 246 (24.8%) 243 (24.5%) 0.876 2,582 (11.2%) 192 (17.4%) < 0.001 163 (15.1%) 186 (17.2%) 0.179
Drug use 2,638 (6.6%) 833 (40.0%) < 0.001 757 (37.5%) 774 (38.3%) 0.581 884 (5.0%) 377 (36.2%) < 0.001 316 (31.9%) 328 (33.1%) 0.565 1,909 (8.3%) 491 (44.5%) < 0.001 469 (43.3%) 471 (43.5%) 0.931
Hypertension: Uncomplicated and 
Complicated 14,616 (36.8%) 1,243 (59.8%) < 0.001 1,178 (58.3%) 1,189 (58.8%) 0.725 7,488 (42.4%) 670 (64.3%) < 0.001 627 (63.2%) 623 (62.8%) 0.852 7,442 (32.4%) 615 (55.8%) < 0.001 584 (53.9%) 596 (55.0%) 0.605
Neurological disorders 2,915 (7.3%) 425 (20.4%) < 0.001 381 (18.9%) 386 (19.1%) 0.841 1,549 (8.8%) 221 (21.2%) < 0.001 197 (19.9%) 187 (18.9%) 0.57 1,460 (6.4%) 224 (20.3%) < 0.001 202 (18.7%) 211 (19.5%) 0.623
Obese 4,445 (11.2%) 319 (15.3%) < 0.001 289 (14.3%) 312 (15.4%) 0.309 2,106 (11.9%) 174 (16.7%) < 0.001 162 (16.3%) 166 (16.7%) 0.809 2,478 (10.8%) 161 (14.6%) < 0.001 147 (13.6%) 158 (14.6%) 0.497
Psychiatric disorders 2,632 (6.6%) 611 (29.4%) < 0.001 531 (26.3%) 559 (27.7%) 0.321 1,221 (6.9%) 288 (27.6%) < 0.001 248 (25.0%) 250 (25.2%) 0.918 1,530 (6.7%) 352 (31.9%) < 0.001 320 (29.5%) 334 (30.8%) 0.512
Renal Failure 3,021 (7.6%) 251 (12.1%) < 0.001 245 (12.1%) 242 (12.0%) 0.885 1,602 (9.1%) 148 (14.2%) < 0.001 153 (15.4%) 139 (14.0%) 0.375 1,491 (6.5%) 115 (10.4%) < 0.001 98 (9.0%) 110 (10.2%) 0.382
*AHRQ restricts reporting of values when n<10
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With regard to procedures during the admission (Table 6), all +A patients had significant 
increases of abdominal CT scans (IBD: 6.8% vs. 9.6%, p < 0.001; UC: 6.9% vs. 9.0%, p < 0.05; 
CD: 7.3% vs. 9.9%, p < 0.01) and antibiotic injections (IBD: 3.1% vs. 5.8%, p < 0.001; UC: 
3.8% vs. 5.5%, p < 0.05; CD: 3.4% vs. 5.8%, p < 0.001). Large intestine and rectal biopsies were 
significantly increased in +A patients compared to -A patients within the IBD study group 
(18.1% vs. 21.7%, p < 0.001; 3.1% vs. 4.3%, p < 0.01). Within the UC and CD study group, 
large intestine and rectal biopsies were not significantly different between the -A and +A 
patients, although UC+A patients did have a trend toward increased large intestine biopsies 
(30.7% vs. 32.6%, p = 0.272). Small intestine biopsies were unchanged between the -A and +A 
patients. Resection of the small intestine was significantly increased in -A patients with IBD 
(1.9% vs. 1.1%, p < 0.01) and CD (2.4% vs. 1.5%, p < 0.05). For the UC study group, -A 
patients displayed a trend toward increased colectomy (4.7% vs. 3.4%, p = 0.077). The 
differences in percentages of colectomy and small intestine resection procedures for the UC and 
CD study groups support the appropriate separation of these patients into their respective groups. 
The median length of stay was unchanged between -A and +A patients in all study groups (4 
days), however the IQR was significantly increased for the -A patients in the IBD (2–7 days vs. 
2–6 days, p < 0.01) and CD (2–7 days vs. 2–6 days, p < 0.05) study groups. In terms of total 
cost, the -A patients had increased total cost during hospitalization for all study groups compared 
to the +A patients (IBD: $13,880.65 vs. $12,262.51, p < 0.0001; UC: $14,564.63 vs. 
$13,217.54, p < 0.05; CD: $13,480.92 vs. $11,794.42, p < 0.001) (Table 6). 
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Table 6. Outcomes of Patients During IBD, UC, or CD Admission
IBD admissions UC admissions CD admissions
IBD-A  
(n=4,965)
IBD+A 
(n=4,013) p value
UC-A  
(n=1,602)
UC+A 
(n=1,437) p value
CD-A 
(n=3,089)
CD+A 
(n=2,548) p value
Diagnoses during admission
C. difficile intestinal infection 98 (2.0%) 105 (2.6%) 0.042 61 (3.8%) 47 (3.3%) 0.427 52 (1.7%) 57 (2.2%) 0.133
Poorly defined intestinal infection 18 (0.4%) 31 (0.8%) 0.009 10 (0.6% 21 (1.5%) 0.022 <10 (%)* 10 (0.4%) 0.514
All intestinal infection 131 (2.6%) 158 (3.9%) 0.001 75 (4.7%) 79 (5.5%) 0.304 65 (2.1%) 78 (3.1%) 0.023
Procedures/Surgery
Abdomen CT Scan 338 (6.8%) 386 (9.6%) < 0.001 110 (6.9%) 130 (9.0%) 0.026 226 (7.3%) 252 (9.9%) 0.001
Biopsy Small Intestine 432 (8.7%) 384 (9.6%) 0.155 158 (9.9%) 134 (9.3%) 0.616 306 (9.9%) 246 (9.7%) 0.752
Resection Small Intestine 92 (1.9%) 44 (1.1%) 0.004 12 (0.7%) 5 (0.3%) 0.139 73 (2.4%) 39 (1.5%) 0.026
Biopsy large intestine 897 (18.1%) 872 (21.7%) < 0.001 492 (30.7%) 468 (32.6%) 0.272 475 (15.4%) 399 (15.7%) 0.771
Colectomy 79 (1.6%) 62 (1.5%) 0.861 75 (4.7%) 49 (3.4%) 0.077 11 (0.4%) 13 (0.5%) 0.376
Biopsy Rectum 156 (3.1%) 173 (4.3%) 0.003 133 (8.3%) 125 (8.7%) 0.695 59 (1.9%) 46 (1.8%) 0.772
Antibiotic injection 154 (3.1%) 234 (5.8%) < 0.001 61 (3.8%) 79 (5.5%) 0.027 105 (3.4%) 148 (5.8%) < 0.001
Mean Length of Stay (Days) 6.08 5.47 < 0.0001 6.3 5.84 0.0547 5.87 5.26 0.0002
Mean Total Charge 43538.74 37743.97 < 0.0001 45817.08 40657.12 0.0058 41881.23 36215.62 0.0001
*AHRQ restricts reporting of values when n<10
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Summary 
Alcohol is known to have numerous deleterious effects in a variety of settings, yet its 
effects in IBD are not well understood. In this study, we described a potential role for alcohol 
affecting the inpatient care of IBD patients. Patients admitted for IBD, and its subsets, UC and 
CD, that had a documented history of alcohol use were more likely to experience increased 
intestinal infections, increased diagnostic procedures, and required more antibiotic injections. 
Based on these results, we concluded that alcohol consumption does impact the clinical 
outcomes of patients admitted for IBD. The observed increase in intestinal infections and 
antibiotic administration seems to suggest that the intestinal microbiomes of IBD patients with a 
documented history of alcohol use might more disrupted than those without a documented 
history of alcohol use. Knowing this, we wanted to examine how the intestinal microbiome is 
affected by the concomitant use of alcohol in the setting of colitis. Therefore, we turned to a 
mouse model of colitis and combined ethanol administration that our lab developed. 
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CHAPTER FOUR 
ALCOHOL ALTERS RATIO OF LACTOBACILLUS TO ENTEROBACTERIACEAE IN 
MOUSE MODEL OF COLITIS 
 
Abstract 
 The intestinal microbiome plays a pivotal role in gut health through processes like 
essential metabolite production and defending against invading pathogens. Any disruptions in the 
microbiome can negatively impact the intestinal health as well as the overall health of the host. 
Pronounced gut microbial changes, characterized by increased Enterobacteriaceae and decreased 
Lactobacillus, have been observed in individuals who have IBD or consume alcohol. These 
bacterial changes are relevant since the Enterobacteriaceae can infiltrate the intestinal mucosa 
and promote inflammation, while the Lactobacillus help prevent inflammation. We anticipate 
that alcohol consumption in the setting of colitis may further alter the intestinal microbiome to 
exacerbate a colitis flare. To assess this, we used a mouse model of dextran sodium sulfate (DSS) 
colitis in conjunction with a binge alcohol regimen. We determined that the intestinal contents of 
DSS+ethanol mice exhibit a 1 log increase in Enterobacteriaceae (p<0.05) and a 0.5 log decrease 
in Lactobacillus compared to DSS+vehicle mice. These bacterial shifts correlate with shorter 
colons and more weight loss. Trends for the microbial changes induced by alcohol in the DSS 
mice could be observed after a single gavage of alcohol, while significant effects manifested 
after three gavages of alcohol. DSS administration decreased intestinal epithelial cell (IEC) tight 
junction and mucin expression compared to control groups, but no additional changes were 
observed in the DSS+ethanol group. Similarly, mice receiving DSS had increased bacterial 
penetration of the intestinal mucosa compared to control groups, but alcohol did not appear to 
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enhance this effect. However, the increased intestinal burden of the pro-inflammatory 
Enterobacteriaceae and their propensity to infiltrate the mucosa, may increase intestinal 
inflammation in the DSS+ethanol mice, exacerbating a flare.  
Introduction 
 Once an individual develops IBD, they will experience episodes of recurring disease, 
known as flares, which are characterized by bloody stools, abdominal discomfort, and weight 
loss. These flares in the disease are frequent, with only 20% of patients with the UC subtype of 
IBD, being flare free after two years(223). Studies examining IBD patients have found that 
alcohol consumption is associated with induction of flare(178), as well as worsening of 
gastrointestinal symptoms(177, 222) and increased intestinal infections(224). These effects may 
arise from alcohol’s ability to alter the intestinal microbiota (189-192, 194), which would 
negatively impact the already altered intestinal microbiome of IBD patients(113-115). In 
particular, both alcohol consumption and IBD are independently characterized by a decrease in 
the Lactobacillus genus(132, 195) and an increase in the Enterobacteriaceae family(113-115, 
194, 195). The observed increase in Enterobacteriaceae is relevant because they can penetrate the 
mucus layer of intestines in patients suffering from ulcerative colitis(113, 114, 173). Studies 
carried out in mouse model of colitis show that this penetration occurs before the onset of 
intestinal tissue damage(174, 175). The decrease in Lactobacillus may further compound this 
effect since it is a beneficial bacterium that promotes intestinal health and also checks the growth 
of Enterobacteriaceae(102-106). Furthermore, studies have determined that the intestinal ratio of 
these two bacteria can be an indicator of gut health(225, 226). Using a mouse model of DSS 
induced colitis and alcohol, we explored whether alcohol has any effect on Enterobacteriaceae 
and Lactobacillus populations in mice treated with DSS and whether changes in these bacteria 
has any relationships with colitis flare. 
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Materials and Methods 
Murine Model of Alcohol and Colitis. 
Male 8-9 week old (∼23–25 g body weight) C57BL/6 mice were obtained from Charles 
River Laboratories (Wilmington, MA). The mouse model used in this study was previously 
described(224). Briefly, mice were randomly assigned to four experimental groups: 
Control+vehicle (Ctrl+V), Control+ethanol (Ctrl+E), Dextran sodium sulfate+vehicle (DSS+V), 
Dextran sodium sulfate+ethanol (DSS+E). As seen in Figure 2, mice were administered either 
normal drinking water or a 2% (w/v) solution of DSS (36,000-50,000 molecular weight; MP 
Biomedicals) ad libitum, starting on day 0 and until day 5. On day 5, DSS was stopped and mice 
received a gavage of either 3g/kg ethanol or water per day until day 7. Mice were euthanized 
three hours after the last gavage. Mice were weighed each day to determine percent weight 
change relative to day 0. Following euthanasia, the large intestine was excised and its length 
determined. 
 
 
 
 
Figure 2. Mouse Model Timeline of DSS-colitis and Alcohol Gavage with 
Experimental Groups. 
 
Experimental groups
Control+Vehicle (Ctrl+V) DSS+V
Control+EtOH (Ctrl+E) DSS+E
2% DSS or H2O
3g/kg EtOH or H2O gavage 
H2O
Day 0 5 6 7
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Blood Alcohol Level Quantification. 
 Plasma samples were assayed on an Analox-GL5 machine (Stourbridge, England) to 
detect alcohol according to manufacturer’s guidelines. The apparatus uses the reaction of alcohol 
and oxygen catalyzed by alcohol oxidase to determined alcohol levels. 
Bacterial DNA Isolation. 
Bacterial DNA was isolated from fecal pellets, large intestine contents, and cecal contents 
using the QIAamp PowerFecal DNA Kit (Qiagen) according manufacturer’s guidelines. The 
optional 5 minute incubation at 2-8°C was not used. Isolated DNA was quantified using a 
NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific). Due to noted PCR inhibition in 
the DNA from the day 5 fecal pellets of the DSS mice, all day 5 fecal pellet DNA samples were 
further purified using the DNeasy PowerClean Pro Cleanup Kit (Qiagen). 
Bacterial DNA qPCR. 
 Primers for bacterial community(227) quantification were as follows: Total bacteria- 
UniF340 (ACTCCTACGGGAGGCAGCAGT) and UniR514 (ATTACCGCGGCTGCTGGC), 
annealing temperature 63°C; Enterobacteriaceae- Uni515F (GTGCCAGCAGCCGCGGTAA) 
Ent826R (GCCTCAAGGGCACAACCTCCAAG), annealing temperature 67°C; Lactobacillus- 
LabF362 (AGCAGTAGGGAATCTTCCA) and LabR677 (CACCGCTACACATGGAG), 
annealing temperature 56°C. 6 uL of of DNA (0.7ng/uL for fecal pellets and large intestine 
contents, or 7 ng/uL cecal contents) was mixed with 2 uL of each forward and reverse primer and 
10 uL of iTaq Universal SYBR Green supermix (Bio-Rad) for a total reaction volume of 20 uL. 
Reactions were performed on a Step One Plus qPCR instrument (Applied Biosystems) and run as 
follows: 95°C for 3 min, 40 cycles of 95°C for 15s, followed by data collection at the annealing 
temperature for 1 min. This was followed by a melt-curve analysis. To interpret bacterial DNA 
relative quantity, Ct values from target bacteria (Enterobacteriaceae or Lactobacillus) were 
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subtracted from total bacteria Ct values to obtain a ΔCt, this was used for the 2^(-ΔCt) 
calculation. The 2^(-ΔCt) value was then log10 transformed. For ratio assessment the 
Lactobacillus 2^(-ΔCt) value was divided by the Enterobacteriaceae value, the result was then 
log10 transformed. 
IEC Isolation. 
Isolation of IECs was performed as described previously (228). The large intestine was 
opened longitudinally and placed in cold PBS containing a 1% penicillin/streptomycin 
(pen/strep) cocktail. The tissues were washed twice with PBS+pen/strep, then place in a 
digestion solution (prewarmed to 37°C) containing 5% heat-inactivated fetal bovine serum 
(FBS), 1% HEPES, 1% pen/strep, 0.5% gentamicin, 5mM EDTA, and 1mM dithiothreitol in 
Hank’s Balanced Salt Solution. The tissues were then placed in a 37°C shaking incubator (250 
rpm) for 20 minutes, then vortexed to dissociate epithelial cells and passed through a 100μm 
filter set in a tube on ice. The prior step was repeated with additional digestion solution. The 
isolated epithelial cells were washed twice in PBS. 
IEC RNA Isolation, cDNA Synthesis, and Gene Expression. 
RNA was isolated from large IECs using the RNeasy Mini Kit (Qiagen) according to 
manufacturer’s guidelines. The RNase-free-DNase Set (Qiagen) was used in conjunction with 
the RNA isolation kit to remove genomic DNA. RNA was quantified using a NanoDrop 2000 
spectrophotometer (Thermo Fisher Scientific). cDNA was synthesized using the High Capacity 
cDNA Reverse Transcription Kit (Thermo Fisher Scientific) and run on a Veriti 96-well Fast 
Thermocycler (Life Technologies). 
Expression of mucins and tight junction proteins were assessed by qPCR using TaqMan 
primer probes and TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific). Reactions 
were performed on a Step One Plus qPCR instrument (Applied Biosystems). Endogenous 
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controls for the targets are as listed on the y-axis of the figure. Targets were assessed using the 
2^(-ΔCt) method and expressed as fold change relative to control+vehicle. 
Large Intestine Mucin Staining. 
A 1 cm portion of the distal large intestine was removed, fixed in Carnoy’s solution, and 
submitted to AML. Samples were embedded in paraffin and sectioned at 5μm onto glass slides. 
Slides were stained with Periodic acid-Schiff and Alcian blue, to detect neutral and acidic 
mucins. Images were taken on an Olympus BX43 Microscope using an Olympus DP26 camera. 
Fluorescent in situ Hybridization. 
Hybridization of distal large intestine sections with bacterial probes was completed as 
described previously(229). Briefly, unstained slides containing colon sections were 
deparaffinized in 3 washes with xylene followed by 3 washes in ethanol. Slides were dried in an 
incubator for 50° C for 25 minutes. Slides were incubated overnight at 50° C with 1 ng/uL of 
probe targeting all bacteria (EUB338: Alexa 555 5’-GCTGCCTCCCGTAGGAGT -3’) in a 
buffer (0.9M NaCl, 20mMTris-HCL, pH 7.5, 0.1% SDS). Slides were washed 3 times in the 
buffer (0.9M NaCl, 20mMTris-HCL, pH 7.5, 0.1% SDS) with 15-minute incubations. Slides 
were then air dried, mounted, and counterstained with ProLong Gold Antifade Mountant with 
DAPI (Thermo Fisher Scientific). Slides were then imaged on a Zeiss Axiovert 200m fluorescent 
microscope and processed by the Axiovision software. A histogram stretch was employed for the 
blue and red channels to spread the image intensities across the entire intensity display range. 
Statistics. 
Linear regression and One-way ANOVA followed by Tukey post-hoc test and Student’s 
t-test were performed using GraphPad Prism software (Version 8.1.2). 
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Results 
Pathology and Blood Alcohol Concentration. 
Consistent with our previous observations(224), mice gavaged with alcohol after DSS 
treatment show more pronounced weight loss and shorter colon lengths (Figure 3A, B). Blood 
alcohol concentrations are also increased in mice receiving ethanol gavage, with a significant 
increase observed between control+ethanol and the DSS+ethanol (Figure 3C). 
 
 
Figure 3. Increased Weight Loss and Shorter Colons in DSS+ethanol Mice. (A) 
Mouse % weight change. (B) Mouse colon length. (C) Mouse plasma blood alcohol 
content. n=6-8 animals per group. Values are mean ± SEM. * p<0.05 by One-Way 
ANOVA with Tukey post-hoc test. 
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Increased Enterobacteriaceae and Decreased Lactobacillus in Colon and Cecal Contents.  
 To assess intestinal bacterial changes, cecal contents and large intestine contents were 
harvested from mice euthanized on day seven, three hours after final gavage. DNA was isolated 
from the large intestine and cecal contents followed by qPCR to detect levels of 
Enterobacteriaceae and Lactobacillus. Both the colon and cecal contents of the DSS mice had 
significantly increased Enterobacteriaceae compared to the control mice (p < 0.05; Figure 4A). 
Furthermore, between the DSS mice, ethanol administration produced a 1 log increase (p < 0.05) 
in the Enterobacteriaceae compared to vehicle administration. Lactobacillus levels were 
decreased 0.5log in DSS+ethanol mice compared to all other experimental groups, which was 
 
Figure 4. Increased Enterobacteriaceae and Decreased Lactobacillus in Large 
Intestine and Cecal Contents of DSS+ethanol Mice. (A) Enterobacteriaceae. (B) 
Lactobacillus. (C) Lactoabacillus:Enterobacteriaceae.* p<0.05 by One-Way ANOVA 
with Tukey post-hoc test. Values are mean ± SEM. RQ: Relative Quantity. 
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not significant, but a trend for significance was observed in the cecal contents (Figure 4B). 
Ratios of Lactobacillus to Enterobacteriaceae have been used as determinants of intestinal 
health(225, 226). This ratio is significantly depressed (> 1.5 log) in DSS administered mice 
compared to control mice (p < 0.05; Figure 4C). Meanwhile between the DSS mice, ethanol 
gavage significantly decreases the Lactobacillus:Enterobacteriaceae ratio in colon (~1 log, p < 
0.05) and cecal (~1.5 log, p<0.05) contents compared vehicle (Figure 4C). 
Longitudinal Assessment of Enterobacteriaceae and Lactobacillus in Fecal Pellets. 
To define the longitudinal changes of the Enterobacteriaceae and Lactobacillus, we 
collected fecal pellets from the mice after weighing and before gavaging with vehicle or ethanol 
on days 5 and 6. Unfortunately, some mice did not produce a pellet, hindering continuous 
sampling from the same mouse, and so data are presented as a summary of each experimental 
group. Despite this, the effect of ethanol on bacterial populations in mice receiving combined 
DSS+ethanol can begin to be appreciated on day 6, one day after the first administration of 
alcohol. From day 5 to day 6, there is a 0.9 log increase in the Enterobacteriaceae from 
DSS+ethanol mice compared to a 0.7 log increase from the DSS+vehicle mice (Figure 5A). 
During this same time period, the Lactobacillus decreases by 0.2 log in the DSS+ethanol mice, 
while there is a slight increase (0.1 log) in the DSS+vehicle mice (Figure 5B). Altogether these 
changes culminate in a ~1 log decrease in the day 5 to day 6 Lactobacillus:Enterobacteriaceae 
ratio of DSS+ethanol mice, whereas this ratio that decreases ~0.5 log compared to DSS+vehicle 
mice (Figure 5C).  
These results suggest that the alcohol treatment elicits an effect on the intestinal 
microbiota after colitis leading to increases in Enterobacteriaceae and decreases in Lactobacillus 
culminating in a decreased Lactobacillus:Enterobacteriaceae ratio. The higher level of 
Enterobacteriaceae and lower level of Lactobacillus may contribute to flare induction. 
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Correlation of Enterobacteriaceae and Lactobacillus to Disease State. 
To further assess how the disease state of the mouse relates to the intestinal bacteria, we 
performed a linear regression of the cecal contents bacteria in relation to the mouse colon length. 
The colon length is a macroscopic indicator of the inflammatory status of the colon, where 
longer colons are healthier and shorter colons are more inflamed. In our experiment, the colon 
length is inversely correlated to cecal content of Enterobacteriaceae (Figure 6A) and directly 
correlated to cecal content of Lactobacillus (Figure 6B). On the scatter plot of the linear 
regression, we observe that the samples from the DSS+ethanol mice have shorter colons in 
conjunction with increased Enterobacteriaceae (Figure 6A) and decreased Lactobacillus (Figure 
6B). In addition, combining data from all four experimental groups, we examined the correlation 
of colon length, day 7 % weight change, and cecal contents bacteria using a Pearson correlation 
(Figure 6C). This revealed that the colon length, and day 7 % weight change are positively 
correlated with Lactobacillus while being inversely correlated with Enterobacteriaceae. 
 
Figure 5. Ratio of Lactobacillus: Enterobacteriaceae Decreases in DSS+ethanol Fecal 
Pellets from Day 5 to Day 6. (A) Enterobacteriaceae. (B) Lactobacillus. (C) 
Lactobacillus: Enterobacteriaceae. n=4-6 animals per group. Values are mean ± SEM. 
RQ: Relative Quantity. 
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Meanwhile, the relationship of Enterobacteriaceae and Lactobacillus are inversely correlated, 
although this result was not significant.  
 
 
 
Figure 6. Enterobacteriaceae Inversely Correlates with Colon Length and 
Lactobacillus Positively Correlates with Colon Length. (A) Cecal Enterobacteriaceae 
vs colon length linear regression. (B) Cecal Lactobacillus vs colon length linear 
regression. (C) Pearson correlation matrix examining colon length, day 7% weight 
change, cecal Enterobacteriaceae, and cecal Lactobacillus. * p<0.05 by Pearson 
correlation. RQ: Relative Quantity. 
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Mucin Alterations After DSS Colitis and Ethanol. 
The healthy large intestine is covered by mucins which act as a barrier to limit bacterial 
interaction with the intestinal epithelium, while in IBD there are marked disruptions of the 
intestinal mucin. This allows for increased interaction of the bacteria with the intestinal 
epithelium and may induce a flare. In our model, we first assessed mucin changes using a PAS-
Alcian blue stain of intestinal sections. We observed that mucin staining was unaffected in the 
control mice but severely decreased in the DSS mice (Figure 7A). The decreased intestinal 
mucin levels in the DSS mice suggests that bacteria interaction with the epithelium is 
uninhibited. We isolated IECs and assessed their expression of mucins and trefoil factor, a 
marker of intestinal health. Mucin 4, mucin 2, intestinal trefoil factor 3 were all significantly 
decreased ~2-fold in the DSS mice and compared to the control mice (p<0.05) (Figure 7B). This 
mirrors the histologic changes observed in Figure 7A. These data suggest that DSS induces a 
primary effect on intestinal mucin depletion, while alcohol has no additive effect.  
Bacterial Infiltration of the Mucosa and Tight Junction Protein Expression. 
To determine bacterial proximity to the epithelial lining, we used fluorescent in situ 
hybridization with a probe targeting all bacteria. We detected an increased presence of bacteria 
in the mucosa of DSS mice, meanwhile bacteria were largely relegated to the intestinal lumen in 
control mice (Figure 8A). IEC RNA expression of tight junction proteins revealed that DSS 
administration led to ~2-fold decrease in ZO-1, Occludin, and Claudin-4 compared to the 
control+vehicle (p<0.05) (Figure 8B). Some direct effects of ethanol appear to also occur as 
there was a significant decrease in Occludin expression in the control+ethanol mice compared to 
the control+vehicle mice, which is not significant between the mice receiving DSS. The 
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combined observations of decreased tight junction expression and increased mucosal infiltration 
suggest that there is increased bacterial translocation, which may further contribute to flare.   
 
 
 
Figure 7. DSS Decreases Intestinal Mucin Staining and IEC Mucin RNA Expression. 
(A) PAS-Alcian blue stained slides. Representative of 6-8 animals pre group. Images 
taken at 400x total magnification.  (B) IEC RNA expression of mucins and intestinal 
trefoil factor. Values are mean ± SEM. * p<0.05 by One-Way ANOVA with Tukey post-
hoc test. Endogenous control in parentheses. 
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Summary 
 The results presented here suggest that in the setting of colitis, alcohol induces additional 
bacterial changes compared to colitis alone. These changes can be seen 24 hours after a single 
 
Figure 8. DSS Increases Infiltration of Intestinal Mucosa and Decreased Expression 
of Tight Junction Proteins. (A) Large intestine sections displaying localization of 
bacteria in red. Dashed line represents interface between intestinal epithelium and the 
intestinal lumen. Representative of 2-3 animals pre group. Images taken at 200x total 
magnification. M: Mucosa; L: Lumen. (B) IEC RNA expression tight junction proteins. 
n=6-8 animals per group. Values are mean ± SEM. * p<0.05 by One-Way ANOVA with 
Tukey post-hoc test. Endogenous control in parentheses. 
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gavage of ethanol as determined by bacterial qPCR of DNA isoalted from fecal pellets on day 6. 
The primary observations were increases in the pro-inflammatory Enterobacteriaceae and 
decreases in the beneficial Lactobacillus. At sacrfice on day seven, after three gavages of ethanol 
have been administered, the changes in Enterobacteriaceae and Lactobacillus are more 
pronounced. Furthermore, the changes in these bacteria directly correlate with weight loss and 
colon length. While changes in IEC RNA expression of mucin and tight junction proteins did not 
differ between the DSS+vehicle and DSS+ethanol mice, the heightened load of 
Enterobacteriaceae suggests that there would be a relative increase in the translocation of this 
bacteria and their products in the DSS+ethanol mice.  
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CHAPTER FIVE 
ALCOHOL INCREASES IEC NOS2 EXPRESSION AFTER COLITIS INDUCTION 
Abstract 
 During flares of IBD, the intestine exhibits increased inflammatory metabolites and 
breakdown products. One metabolite particularly enriched during flares of IBD is nitrate. This 
metabolite arises from the reaction of nitric oxide, derived from nitric oxide synthase 2 (Nos2), 
and oxygen radicals generated by various inflammatory processes. The Enterobacteriaceae can 
use nitrate as an energy source while other intestinal bacteria are unable or have a limited 
capacity to do so. Using the mouse model of colitis and alcohol we assessed expression and 
localization of Nos2 as well as the expression of enzymes that may contribute to the pool of 
reactive oxygen in the intestine. After colitis induction, we observed that the DSS+ethanol mice 
had a 1.5-fold increase in IEC expression of Nos2 compared to DSS+vehicle (p<0.05), which 
was also verified by western blot. Immunostaining of intestinal swiss rolls revealed increased 
Nos2 localization to the apical surface of the intestinal epithelium from DSS+ethanol mice 
compared to DSS+vehicle mice. Colitis also induced the expression of IEC dual oxidase 2 
(Duox2), which can contribute to nitrate production via generation of reactive oxygen species. 
We further observed that after colitis induction, mice receiving a single gavage of ethanol 
exhibited a trend for increased IEC Nos2 expression. These results suggest that in the setting 
colitis, ethanol can have a potentiating effect on the expression of IEC Nos2. 
Introduction 
 Bacteria are capable of using a number of substrates for energy production and, 
depending on the surrounding environment, can switch their metabolism to utilize the substrate 
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most advantageous to their growth. In the healthy large intestine, fermentation of indigestible 
polysaccharides is the primary source of ATP generation(144). Due to their fermentation 
efficiency, the Bacteroidetes and Firmicutes phyla dominate the large intestine, comprising at 
least 90% of all bacterial populations(27, 35). However, during flares of UC, these is 
upregulation of the intestinal enzyme Nos2 and its product nitric oxide, which can eventually 
promote the production of a non-fermentable energy source, nitrate(147). 
There are three nitric oxide synthase isozymes, each of which catalyze the reaction of L-
arginine and oxygen to form L-citrulline and nitric oxide. Nos1 and Nos3 are constitutively 
expressed in neuronal tissue and endothelial tissue, respectively, while Nos2 is inducible and can 
be expressed in a variety of cells. Aside from expression differences, these enzymes also differ in 
the regulation of their activity. Nos1 and Nos3 activity is regulated by calcium fluxes and can 
produce nanomolar concentrations of nitric oxide for brief periods of time. In contrast, Nos2 is 
not regulated by calcium and thus, once expressed, can produce micromolar concentrations of 
nitric oxide for long durations(230). Nos2 can be induced by a variety of factors including LPS, 
tumor necrosis α, interleukin 1β, and interferon γ(231).  
In the oxidative environment of an IBD flare, the nitric oxide reacts with reactive oxygen 
species leading to the formation of peroxynitrite, which can oxidize numerous biological 
components and nitrosylate protein tyrosine residues(232). In fact, models of colitis have been 
generated simply by administering peroxynitrite(233) and a study found increased concentrations 
of peroxynitrite in the intestine of UC patients(234). However, peroxynitrite can also 
spontaneously degrade into nitrate(232), which can be used by facultative anaerobic bacteria, 
like the Enterobacteriaceae, as a terminal electron acceptor in the process of anaerobic 
respiration(155, 235), while the Bacteroidetes and Firmicutes cannot(156). Furthermore, the 
reduction of nitrate during anaerobic respiration is much more energetically favorable than 
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polysaccharide fermentation(155), which allows for Enterobacteriaceae overgrowth(157). To 
facilitate the utilization of this precious energy source, the Enterobacteriaceae encode a 
chemoreceptor that detects nitrates and initiates subsequent chemotaxis toward the nitrate 
source(236, 237).  
In the previous chapter, we identified that the combined effect of colitis and alcohol 
administration led to increased intestinal Enterobacteriaceae. As the Nos2 metabolite nitrate has 
been linked to the growth of Enterobacteriaceae, we studied the expression of intestinal Nos2 in 
our model. We observed that at the RNA and protein level Nos2 IEC expression was 
significantly increased in the combined DSS+ethanol compared to the DSS+vehicle. Nos2 
immunohistochemistry of intestinal swiss rolls, revealed a similar result, with enhanced Nos2 
staining localized to the apical surface of the intestinal epithelium in the DSS+ethanol relative to 
DSS+vehicle. This suggests that alcohol may contribute to the expansion of Enterobacteriaceae 
by increasing the expression of epithelial Nos2 and thus an increase in intestinal nitrate. 
Materials and Methods 
Murine Model of Alcohol and Colitis. 
Male 8-9 week old (∼23–25 g body weight) C57BL/6 mice were obtained from Charles 
River Laboratories (Wilmington, MA). The mouse model used in this study was previously 
described(224). Briefly, mice were randomly assigned to four experimental groups: 
Control+Vehicle (Ctrl+V), Control+Ethanol (Ctrl+E), Dextran sodium sulfate+Vehicle 
(DSS+V), Dextran sodium sulfate+Ethanol (DSS+E). As seen in Figure 2, mice were 
administered either normal drinking water or a 2% (w/v) solution of DSS (36,000-50,000 
molecular weight; MP Biomedicals) ad libitum, starting on day 0 and until day 5. On day 5, DSS 
was stopped and mice received a gavage of either 3g/kg ethanol or water per day until day 7. 
Mice were euthanized three hours after the last gavage. Blood was collected via cardiac puncture 
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and processed for plasma. Mice were weighed each day to determine percent weight change 
relative to day 0. Following euthanasia, the large intestine was excised and its length determined. 
For the single gavage experiment, the model proceeded as described above, however, 
mice were only given one gavage of alcohol or vehicle on day 5, followed by euthanasia 3 hours 
after the gavage.  
IEC Isolation. 
Isolation of large IECs was performed as described previously (228). The large intestine 
was opened longitudinally and placed in cold PBS containing a 1% penicillin/streptomycin 
(pen/strep) cocktail. The tissues were washed twice with PBS+pen/strep, then place in a 
digestion solution (prewarmed to 37°C) containing 5% heat-inactivated fetal bovine serum 
(FBS), 1% HEPES, 1% pen/strep, 0.5% gentamicin, 5mM EDTA, and 1mM dithiothreitol in 
Hank’s Balanced Salt Solution. The tissues were then placed in a 37°C shaking incubator (250 
rpm) for 20 minutes, then vortexed to dissociate epithelial cells and passed through a 100μm 
filter set in a tube on ice. The prior step was repeated with additional digestion solution. The 
isolated epithelial cells were washed twice in PBS. 
RNA Isolation, cDNA Synthesis, and Gene Expression. 
RNA was isolated from large IECs or total tissue using the RNeasy Mini Kit (Qiagen) 
according to manufacturer’s guidelines. The RNase-free-DNase Set (Qiagen) was used in 
conjunction with the RNA isolation kit to remove genomic DNA. RNA was quantified using a 
NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific). cDNA was synthesized using the 
High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) and run on a Veriti 
96-well Fast Thermocycler (Life Technologies). 
Expression of targets was assessed by qPCR using TaqMan primer probes and TaqMan 
Fast Advanced Master Mix (Thermo Fisher Scientific). Reactions were performed on a Step One 
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Plus qPCR instrument (Applied Biosystems). Endogenous controls for the targets are as listed on 
the y-axis of the figure. Targets were assessed using the 2^(-ΔCt) method and expressed as fold 
change relative to Control+Vehicle. 
Protein Quantification and Western Blot of Nos2. 
IECs were homogenized in 1x Cell Lysis Buffer (Cell Signaling Technologies) supplemented 
with 1x Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). Protein was 
quantified using the DC Protein Assay (Bio-Rad). Protein was separated using SDS-PAGE using 
Bolt Bis-Tris gels (Thermo Fisher Scientific) and then transferred to a PVDF Membrane using a wet 
transfer method. Membrane was blocked with milk, washed with TBS, then incubated overnight with 
Nos2 antibody (Cell Signaling Technology). After washing with TBST, the membrane was incubated 
with HRP-linked secondary antibody (Cell Signaling Technology) and developed using Western 
Lightning Plus-ECL, Enhanced Chemiluminescence Substrate (Perkin Elmer). Membrane was 
imaged on a ChemiDoc (Bio-Rad) and densitometry analysis performed using ImageLab software 
(Bio-Rad). Afterwards the blot was stripped using Restore Plus Stripping Buffer (Thermo Fisher 
Scientific) and then probed for β-actin (Cell Signaling Technologies), which was used for band 
normalization.  
Plasma Nitrate+Nitrite Assessment. 
Amicon Ultra-0.5 mL Centrifugal Filters were first rinsed with molecular grade water. After 
rinsing, plasma was applied to the column and centrifuged. The filtrate was used to asses total nitric 
oxide metabolites (nitrate+nitrite) using a Nitrate/Nitrite Colorimetric Assay Kit (Cayman Chemical) 
according to manufacturer’s guidelines.  
Immunohistochemistry of Large Intestine Swiss Rolls. 
After sacrifice, the large intestine of the mouse was excised, opened longitudinally, and 
cleared of any fecal matter. The intestine was rolled from the distal end to the proximal, stabilized 
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with a syringe needle, placed in a cassette, and then fixed in 10% neutral buffered formalin. Tissues 
were embedded in paraffin and sectioned at 5 uM onto glass slides. Slides were deparaffinized by 
incubating in graded washes of xylene and then ethanol. Deparaffinized slides were incubated in 
0.2% triton X-100 PBS for 10 minutes, followed by boiling in sodium citrate buffer (Abcam) for 30 
minutes, then removed from heat and allowed to cool for 45 minutes. Slides were then incubated at 
room temperature for 2 hours with Nos2 antibody (Cell Signaling Technologies, 1:400) or Nos2 
antibody and Anti-neutrophil antibody (Abcam, 1:50). Slides were washed three times with PBS and 
then incubated with goat anti-rabbit AlexaFlour555 (Thermo Fisher Scientific, 1:200) or goat anti-
rabbit AlexaFlour488 (Thermo Fisher Scientific, 1:200) and goat anti-rat AlexFlour555 (Thermo 
Fisher Scientific, 1:200). Slides were then counterstained and mounted with ProLong Gold 
Antifade Mountant with DAPI (Thermo Fisher Scientific). Slides were then imaged on a Zeiss 
Axiovert 200m fluorescent microscope and processed by the Axiovision software. For Nos2 
swiss roll staining, in order to capture the entire swiss roll multiple images were taken at 25x and 
then Adobe Photoshop was used to merge images together. For all flourescence images, a 
histogram stretch was employed in Adobe Photoshop for the blue, red, and green channels to 
spread the image intensities across the entire intensity display range.  
Statistics. 
One way ANOVA followed by Tukey post-hoc test was used for significance analysis 
using GraphPad Prism software (Version 8.1.2). 
Results 
Increased Intestinal Expression of Reactive Oxygen Generating Enzymes After DSS. 
The production of nitrate within the intestine requires both the presence of oxygen radicals 
and nitric oxide(35). These components can react, producing peroxynitrite, which can spontaneously 
 56 
degrade into nitrate(232), a substrate that facultative anaerobic bacteria, like the 
Enterobacteriaceae, can use as an energy source(235).  
We first examined IEC RNA expression of Nicotinamide adenine dinucleotide phosphate 
oxidase 1 (Nox1) and Duox2, both of which can lead to the production of reactive oxygen species. 
No significant changes were observed in the expression of Nox1 (Figure 9A). Duox2 expression was 
significantly increased in the mice receiving DSS compared to control but not significantly altered 
after alcohol gavage (Figure 9B).  
After consuming alcohol, bloodstream levels of alcohol can mirror those seen along the 
gastrointestinal tract(202), while the alcohol metabolite, acetaldehyde, is produced in appreciable 
 
Figure 9. DSS Increases IEC RNA Expression of Duox2 and Decreases Expression of 
Adh1. (A) NADPH oxidase 1. (B) Dual Oxidase 1. (C) Alcohol dehydrogenase 1. (D) 
Catalase. Values are mean ± SEM. * p<0.05 by One-Way ANOVA with Tukey post-hoc 
test. Endogenous control in parentheses. 
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amounts within the intestine(203, 204). This increase in acetaldehyde is attributed to metabolism 
that occurs by the IECs and the intestinal bacteria(203, 204). As the process of alcohol 
metabolism through its endogenous reactions and acetaldehyde production can participate in 
reactive oxygen generation(207) we examined IEC RNA expression of alcohol metabolizing 
enzymes. Alcohol dehydrogenase (Adh1), the enzyme responsible for the bulk of ethanol metabolism 
in the human body, was significantly decreased in mice receiving DSS compared to control mice, 
with no significant difference observed between DSS+vehicle and DSS+ethanol (Figure 9C). 
Ethanol can also be metabolized by catalase and cytochrome P450 2E1. Catalase RNA expression 
was unchanged (Figure 9D), while Cytochrome P450 2E1 RNA levels were undetectable (data not 
shown).  
Increased IEC Expression of Nos2 in DSS+ethanol. 
The other component of nitrate generation is nitric oxide, which is produced by Nos2. We 
examined RNA expression of Nos2 in both total large intestine tissue homogenates and IECs. While 
Nos2 RNA expression was observed to be increased in total tissue from DSS mice compared to 
control (Figure 10A), examination of IECs provided a clearer picture of the Nos2 changes between 
groups, displaying a significant 1.5-fold increase in DSS+ethanol compared to DSS+vehicle (Figure 
10B). This increase was confirmed by assessment of IEC Nos2 protein levels (Figure 10C), 
followed by densitometry (Figure 10D). We attempted to assess nitrate levels in cecal scrapings 
however no nitrates were detectable (data not shown). This may be due to either our sample 
preparation or the kit we used may have lacked the sensitivity to detect nitrates. Increases in serum 
nitrate concentration has been observed in active IBD(238), thus we examined plasma nitrate levels 
in mice from our model. Although nitrates were increased in both DSS+vehicle and DSS+ethanol, 
these results were not significant between any of the experimental groups (Figure 10E). These data 
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indicate that DSS+ethanol IECs significantly upregulate Nos2 expression relative to the other 
experimental groups. 
 
 
 
 
Figure 10. DSS+ethanol Increases IEC Nos2 Expression. (A) Total tissue Nos2 RNA 
expression. (B). IEC Nos2 RNA expression. (C) IEC Nos2 Western blot. (D) 
Densitometry of Nos2 Western blot in (C). (D) Plasma nitrate+nitrite. Values are mean ± 
SEM. * p<0.05 by One-Way ANOVA with Tukey post-hoc test. Endogenous control in 
parentheses. 
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Increased Localization of Nos2 to the Intestinal Epithelium in DSS+ethanol. 
We next wanted to determine the localization of Nos2 within the intestine. In control mice 
there was no detectable staining of Nos2 (Figure 11). In the DSS mice, Nos2 was observed and 
primarily localized to the apical surface of the epithelium (Figure 11). This coincides with the 
localization of Nos2 observed in histological samples from IBD patients(234). Nos2 staining in 
the DSS+ethanol mice appeared to be increased in terms of intensity, and distribution along the 
length of the intestine as well as the intestinal crypt.  
Since neutrophils are a potential source of Nos2 and their invasion into the intestine is 
well documented in both UC(239) and mouse models of colitis(240), we wanted to identify 
whether neutrophils were potentially contributing to nitric oxide generation. To accomplish this, 
we used antibodies specific to Nos2 and neutrophils to detect colocalization of Nos2 with 
neutrophils in our model. While we were able to identify neutrophils in the intestines of mice 
receiving DSS, we did not observe colocalization of Nos2 with the neutrophil marker. This 
suggests that the IECs are the primary source of Nos2 and thus the major contributor to nitric 
oxide for generation of nitrate (Figure 12). 
Single Gavage of Ethanol has Slight Potentiating Effect on Nos2 IEC RNA Expression. 
The effect of a single dose of ethanol was assessed in our model by sacrificing mice on 
day five, three hours after gavage, as observed in (Figure 13A). The colon lengths of the DSS 
mice were shorter compared to the control mice, but only significant between control+ethanol 
mice (Figure 13B). No significant % weight change observed on day five between all 
experimental groups (Figure 13C). Similar to the results presented in Figure 9B, IEC Duox2 
RNA expression was significantly increased in the mice receiving DSS compared to control mice 
(Figure 13D). DSS also increased epithelial expression of Nos2 compared to control mice 
(Figure 13E). While the Nos2 RNA expression was increased in mice receiving a single gavage 
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of alcohol following DSS compared to DSS+control mice, the increase in Nos2 was not found to 
be significant. This seems to indicate that in the setting of DSS-induced colitis, a single gavage  
may also augment Nos2 expression but is limited compared to the effect by three gavages. 
 
 
 
Figure 11. DSS+ethanol Increases Nos2 Immunostaining which is Localized to the 
Intestinal Epithelium. Square images consist of separate images taken at 25x and 
merged together. Insert images for DSS+V and DSS+E taken at 200x. Ctrl images 
representative of 2 animals per group. DSS images are of three animals per group. 
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Figure 12. Nos2 does Not Colocalize with Infiltrating Neutrophils After DSS 
Treatment. All images are at 200x, unless noted otherwise. Images representative of 1-2 
animals per group. 
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Figure 13. Single Gavage of Ethanol Potentiates IEC Nos2 Expression After DSS but 
Not Significantly Compared to DSS+vehicle. (A) Model of single gavage 
administration. (B) Colon length. (C) Day 5 % weight change. (D) Duox2 IEC RNA 
expression. (E) Nos2 IEC RNA expression. Values are mean ± SEM. * p<0.05 by One-
Way ANOVA with Tukey post-hoc test. Endogenous control in parentheses. 
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Summary 
The results indicate that in the setting of colitis, alcohol may promote the growth of 
Enterobacteriaceae by increasing the expression of Nos2. The increased expression of Nos2 likely 
contributes to increased intestinal nitrate, a favorable energy source for the Enterobacteriaceae. The 
expression of Nos2 in the intestine was localized to the epithelial layer specifically the apical surface, 
suggesting that nitric oxide is being released directly into the intestinal lumen. While neutrophils 
were present infiltrating into the intestinal crypts, Nos2 was not detected within the neutrophils, thus 
IECs may be a primary source of nitric oxide in the intestine. Upon release, nitric oxide can react 
with the reactive oxygen substances produced from Duox2 or other reactive processes. Interestingly, 
IEC RNA expression of alcohol dehydrogenase was decreased in DSS, suggesting that ethanol may 
be present in larger quantities in the intestine and thereby contribute to a more reactive environment.  
Furthermore, in DSS mice, ethanol’s potentiating effect on IEC Nos2 expression could be observed 
even after a single dose compared to DSS mice receiving vehicle. 
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CHAPTER SIX 
ENTEROBACTERIACEAE PERSIST AFTER ALCOHOL ADMINISTRATION DESPITE 
INHIBITION OF NOS2 ACTIVITY AND NITRATE UTILIZATION 
 
Abstract 
 We observed that the combination of colitis and alcohol increased IEC expression of 
Nos2 compared to colitis and a vehicle. This suggests that the intestines of DSS+ethanol mice 
exhibit increased levels of intestinal nitric oxide, which in turn can lead to increased nitrates, and 
a bloom in Enterobacteriaceae. To mitigate the expansion of Enterobacteriaceae, we employed 
two treatments, L-N6-(1-iminoethyl)-L-lysine dihydrochloride (L-NIL), which inhibits Nos2 
activity, and tungstate (W), which inhibits nitrate utilization. Global assessment of the 
microbiome via 16S sequencing, indicated that all mice receiving DSS had decreased alpha 
diversity compared to the controls. The DSS+ethanol mice had significantly decreased bacterial 
community evenness compared to DSS+vehicle mice, yet no significant change in bacterial 
community richness was observed between the DSS mice. In addition, DSS altered beta 
diversity, with notable differences being observed between the DSS+vehicle groups and the 
DSS+ethanol groups. In depth examination of bacteria at the phylum and family levels revealed 
additional changes between groups. The DSS+vehicle mice that received either of the L-NIL or 
Tungstate treatment exhibited decreased Enterobacteriaceae. However, the DSS+ethanol group 
that received these treatments exhibited levels of Enterobacteriaceae that appeared to be 
intermediate to the mice receiving either DSS+vehicle and DSS+ethanol. Each of the 
experimental groups was also characterized by increases in select taxa of bacteria. Due to the 
intermediate changes in the Enterobacteriaceae of the DSS+ethanol mice that received treatment, 
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we examined IEC RNA expression of Nos2 and unexpectedly found its expression was 
decreased in DSS+ethanol compared to DSS+vehicle. Examination of prior Nos2 expression 
data in relation to weight loss indicated that once a certain weight loss threshold was met, Nos2 
expression began to decrease rather than increase. The treatments had some benefit by 
preventing weight loss, increasing colon length, and limiting intestinal damage. In a separate set 
of experiments, we assessed nitrate dependent growth in the DSS+vehicle and DSS+ethanol 
experimental groups using nitrate reductase proficient or deficient bacteria. While there appeared 
to be a small benefit to nitrate dependent growth, differences between DSS+ethanol and 
DSS+vehicle appeared either negligible or slightly favoring nitrate dependent growth in 
DSS+ethanol. Limited colonization of these bacteria in the mice may have played a role in this 
result. Combined treatment with both L-NIL and tungstate to target the respective nitrate 
production and utilization pathways, led to decreased Enterobacteriaceae growth in both 
DSS+vehicle and DSS+ethanol but the effect of ethanol in reducing Lactobacillus persisted. 
Lastly, alterations in the cecal content SCFAs were assessed, revealing a strong effect of DSS in 
reducing SCFAs, with smaller effects attributable to ethanol administration. 
Introduction 
 In mouse models, Nos2 inhibition or Nos2 deficiency decreases susceptibility to 
colitis(241). Initial studies attributed this beneficial effect largely relied on limitation of general 
oxidative stress, however, more recent studies have proposed that this effect may be mediated in 
part by decreased growth of the pro-inflammatory bacteria like Enterobacteriaceae(242). In order 
to use nitrates as an energy source, the Enterobacteriaceae encode three nitrate reductases: two 
membrane bound nitrate reductases (NarZ, NarG), and one periplasmic nitrate reductase (NapA) 
(155). Deleting these genes in E. coli, a representative Enterobacteriaceae bacterium, inhibits 
growth in inflammatory situations relative to wild-type E. coli(243, 244). The nitrate reductase 
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enzymes require a molybdenum containing molybdopterin cofactor, which catalyzes the 
reduction of nitrate(245). Molybdenum can be replaced with tungstate, which inactivates the 
molybdopterin cofactor and prevents bacterial utilization of nitrates as an energy source(246). A 
previous study has demonstrated that tungstate treatment inhibited  the growth of 
Enterobacteriaceae as well as reduced the severity of intestinal damage in a mouse model of 
colitis, suggesting a  role of Enterobacteriaceae in the disease pathogenesis of colitis(247). 
 To examine whether decreased nitrates or decreased nitrate utilization could ameliorate 
the bacterial changes induced by the combined insult of alcohol and colitis, we treated the mice 
with L-NIL and tungstate. As has been shown previously the dysbiosis induced by DSS was 
limited by L-NIL and tungstate, however, this effect appeared to be blunted when these 
treatments were administered in the combined setting of alcohol and colitis. This suggests that 
other effects induced by ethanol aside from nitrate and nitrate utilization may play a role in the 
bacterial changes elicited by ethanol and colitis.  
Materials and Methods 
Murine Model of Alcohol and Colitis with Either L-NIL or Tungstate Treatment and 
Combined L-NIL and Tungstate Treatment. 
Male 8-9 week old (∼23–25 g body weight) C57BL/6 mice were obtained from Charles 
River Laboratories (Wilmington, MA). The mouse model used in this study was previously 
described(224). Briefly, mice were randomly assigned to eight experimental groups: 
control+vehicle (Ctrl+V), control+ethanol (Ctrl+E), dextran sodium sulfate+vehicle (DSS+V), 
dextran sodium sulfate+ethanol (DSS+E), DSS+vehicle+L-NIL (DSS+V+L), DSS+ethanol+L-
NIL (DSS+E+L), DSS+vehicle+tungstate (DSS+V+W), and DSS+ethanol+tungstate 
(DSS+E+W). As seen in Figure 14, mice were administered either normal drinking water or a 
2% (w/v) solution of DSS (36,000-50,000 molecular weight; MP Biomedicals) ad libitum, 
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starting on day 0 and until day 5. On day 4 mice in the L-NIL and tungstate treatment groups had 
their water bottle replaced with either 2% DSS with 1mg/mL L-NIL or 2% DSS with 0.2% 
tungstate.  On day 5, DSS was stopped and water bottle solutions were replaced with either L-
NIL, Tungstate, or normal drinking water. Mice then received a gavage of either 3g/kg ethanol or 
water per day until day 7. Mice were euthanized three hours after the last gavage. Mice were 
weighed each day to determine percent weight change relative to day 0. Following euthanasia, 
the large intestine was excised and its length determined. 
Using only DSS+vehicle and DSS+ethanol, the treatment paradigm proceeded as shown 
in Figure 6.1 and described as above, except the water bottles contained both L-NIL and 
Tungstate. This led to the formation of 2 groups: DSS+V+L-NIL+Tungstate (DSS+V+L+W) and 
DSS+E+L-NIL+Tungstate (DSS+E+L+W). DNA was isolated from cecal contents for bacterial 
qPCR. 
 
 
 
 
Figure 14. Colitis and Alcohol Model with L-NIL and Tungstate Treatment 
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Bacterial DNA Isolation.  
Bacterial DNA was isolated from fecal pellets, large intestine contents, and cecal contents 
using the QIAamp PowerFecal DNA Kit (Qiagen) according manufacturer’s guidelines. The 
optional 5 minute incubation at 2-8°C was not used. Isolated DNA was quantified using a 
NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific).  
Microbial Community Characterization Using Deep Sequencing of 16S rRNA Gene 
Amplicons. 
Genomic DNA extracted from soil was PCR amplified with primers CS1_515Fb and 
CS2_806Rb (modified from the primer set employed by the Earth Microbiome Project (EMP; 
GTGYCAGCMGCCGCGGTAA and GGACTACNVGGGTWTCTAAT) targeting the V4 
regions of microbial small subunit ribosomal RNA genes. Amplicons were generated using a 
two-stage “targeted amplicon sequencing (TAS)” protocol (248, 249). The primers contained 5’ 
common sequence tags (known as common sequence 1 and 2, CS1 and CS2) as described 
previously (250, 251). First stage PCR amplifications were performed in 10 microliter reactions 
in 96-well plates, using the MyTaq HS 2X mastermix. PCR conditions were 95°C for 5 minutes, 
followed by 28 cycles of 95°C for 30”, 55°C for 45” and 72°C for 60”. 
Subsequently, a second PCR amplification was performed in 10 microliter reactions in 
96-well plates. A mastermix for the entire plate was made using the MyTaq HS 2X mastermix. 
Each well received a separate primer pair with a unique 10-base barcode, obtained from the 
Access Array Barcode Library for Illumina (Fluidigm, South San Francisco, CA; Item# 100-
4876). These AccessArray primers contained the CS1 and CS2 linkers at the 3’ ends of the 
oligonucleotides. Cycling conditions were as follows: 95°C for 5 minutes, followed by 8 cycles 
of 95°C for 30”, 60°C for 30” and 72°C for 30”. A final, 7 minute elongation step was performed 
at 72°C. Samples were pooled in equal volume using an EpMotion5075 liquid handling robot 
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(Eppendorf, Hamburg, Germany). The pooled library was purified using an AMPure XP cleanup 
protocol (0.6X, vol/vol; Agencourt, Beckmann-Coulter) to remove fragments smaller than 300 
bp. The pooled libraries, with a 20% phiX spike-in, were loaded onto an Illumina MiniSeq mid-
output flow cell (2x153 paired-end reads). Fluidigm sequencing primers, targeting the CS1 and 
CS2 linker regions, were used to initiate sequencing. De-multiplexing of reads was performed on 
instrument.  Library preparation, pooling, and sequencing were performed at the University of 
Illinois at Chicago Sequencing Core (UICSQC). 
Sequencing Data Processing and Analysis. 
Raw data was demultiplexed, filtered on quality, and merged using dada2 v1.12 
(https://benjjneb.github.io/dada2) run on R version 3.5.2. Afterwards data was imported into 
Quantitative Insights into Microbial Ecology 2 (QIIME2) v2019.1 ((https://qiime2.org/) to align 
sequences and identity amplicon sequence variants (ASVs) against a Naive Bayes classifier 
trained on Silva 132 99% OTUs from 515F/806R region of sequences 
(https://docs.qiime2.org/2019.1/data-resources/). Alpha and beta diversity analysis was 
performed using the QIIME2 program. Alpha diversity analysis was performed after rarefying to 
59,000 reads. No rarefication was performed for beta diversity analysis.  Alpha diversity 
significance was assessed using a Kruskal-Wallis pairwise analysis followed by Benjamini & 
Hochberg correction, while beta diversity was assessed using PERMANOVA, followed by 
Benjamini & Hochberg correction. * q < 0.05. 2-D PCoA plots were also generated using the 
QIIME2 program. 
To identify differentially abundant bacteria, the sequencing data taxonomy was collapsed 
to the family level then applied to the Linear discriminant analysis (LDA) Effect Size (LEfSe) 
method was used from the Galaxy website (http://huttenhower.sph.harvard.edu/galaxy/) with the 
following parameters: Kruskal-Wallis test alpha value of 0.05; Logarithmic LDA score for 
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discriminative features of 2.0; All-against-all strategy for multi-class analysis. LDA plot and 
cladograms were edited in Adobe Illustrator. 
Bacterial DNA qPCR. 
 Primers for bacterial community(227) quantification were as follows: Total bacteria- 
UniF340 (ACTCCTACGGGAGGCAGCAGT) and UniR514 (ATTACCGCGGCTGCTGGC), 
annealing temperature 63°C; Enterobacteriaceae- Uni515F (GTGCCAGCAGCCGCGGTAA) 
Ent826R (GCCTCAAGGGCACAACCTCCAAG), annealing temperature 67°C; Lactobacillus- 
LabF362 (AGCAGTAGGGAATCTTCCA) and LabR677 (CACCGCTACACATGGAG), 
annealing temperature 56°C. 6 uL of of DNA (0.7ng/uL for fecal pellets and large intestine 
contents, or 7 ng/uL cecal contents) was mixed with 2 uL of each forward and reverse primer and 
10 uL of iTaq Universal SYBR Green supermix (Bio-Rad) for a total reaction volume of 20 uL. 
Reactions were performed on a Step One Plus qPCR instrument (Applied Biosystems) and run as 
follows: 95°C for 3 min, 40 cycles of 95°C for 15s, followed by data collection at the annealing 
temperature for 1 min. This was followed by a melt-curve analysis. To interpret bacterial DNA 
relative quantity, Ct values from target bacteria (Enterobacteriaceae or Lactobacillus) were 
subtracted from total bacteria Ct values to obtain a ΔCt, this was used for the 2^(-ΔCt) 
calculation. The 2^(-ΔCt) value was then log10 transformed. For ratio assessment the 
Lactobacillus 2^(-ΔCt) value was divided by the Enterobacteriaceae value, the result was then 
log10 transformed. 
IEC Isolation. 
Isolation of large IECs was performed as described previously (228). The large intestine 
was opened longitudinally and placed in cold PBS containing a 1% penicillin/streptomycin 
(pen/strep) cocktail. The tissues were washed twice with PBS+pen/strep, then place in a 
digestion solution (prewarmed to 37°C) containing 5% heat-inactivated fetal bovine serum 
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(FBS), 1% HEPES, 1% pen/strep, 0.5% gentamicin, 5mM EDTA, and 1mM dithiothreitol in 
Hank’s Balanced Salt Solution. The tissues were then placed in a 37°C shaking incubator (250 
rpm) for 20 minutes, then vortexed to dissociate epithelial cells and passed through a 100μm 
filter set in a tube on ice. The prior step was repeated with additional digestion solution. The 
isolated epithelial cells were washed twice in PBS. 
RNA Isolation, cDNA Synthesis, and Gene Expression. 
RNA was isolated from large IECs or total tissue using the RNeasy Mini Kit (Qiagen) or 
the mirVana miRNA Isolation Kit (Thermo Fisher Scientific) according to manufacturer’s 
guidelines. The RNase-free-DNase Set (Qiagen) was used in conjunction with the RNeasy Mini 
Kit to remove genomic DNA. RNA was quantified using a NanoDrop 2000 spectrophotometer 
(Thermo Fisher Scientific). cDNA was synthesized using the High Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher Scientific) and run on a Veriti 96-well Fast Thermocycler (Life 
Technologies). 
Histology and Histopathology. 
A 1 cm portion of the distal large intestine was removed, fixed in Carnoy’s solution, and 
submitted to AML. Samples were embedded in paraffin and sectioned at 5μm onto glass slides, 
followed by H&E stain. These sections were then scored based on a 0-4 point scale examining 
exudate, epithelial damage, polymorphonuclear leukocyte invasion, submucosal edema, and 
necrosis. The values from each of these categories were summed to produce the combined 
histopathology score.   
Competitive Index Experiments. 
Studies assessing the competitive advantage of nitrate utilization in the intestine have knocked 
out the three nitrate reductase enzymes from Escherichia coli, a representative bacterium of the 
Enterobacteriaceae(242, 243). This knockout bacterium (ΔNR) and wildtype with nitrate 
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reductases intact (WT) have been provided to us by Dr. Tyrrell Conway of Oklahoma State 
University. The bacteria are derived from the E. coli MG1655 K-12 strain. The WT has a 
genomic integrated antibiotic resistance to both streptomycin (Str) and nalidixic acid (Nal), while 
the ΔNR has genomic integrated resistance to both Str and chloramphenicol (Cat). The 
experiment was conducted as described earlier in Figure 4.1 with modifications. Instead of using 
Charles River mice, male 8-9 week old (∼23–25 g body weight) C57BL/6 were obtained from 
Jackson Labs. In addition, on day 4 of the mice received a 5 x 108 CFU gavage of each WT and 
ΔNR in 0.1 mL of LB media generating two experimental groups: DSS+V+E. coli (DSS+V+E), 
and DSS+E+E. coli (DSS+E+E). Fresh fecal pellets were collected on ice on day 5, 6, and 7, 
weighed, then processed immediately by homogenizing in 1 mL sterile PBS and plating in serial 
10-fold dilutions on selective MacConkey agar plates. The plates contained either Str(50 µg/mL) 
and Nal(50 µg/mL) or Str(50 µg/mL) and Cat(30 µg/mL) for selection of the WT and ΔNR 
bacteria, respectively. This same process was used for intestinal contents removed from the mice 
after euthanasia on day 7. After overnight incubation at 37°C overnight, colony forming units 
(CFUs) were counted and normalized to gram feces. A bacterial competitive index for each 
mouse will be determined by dividing the WT CFUs over the ΔNR CFUs. 
SCFA Analysis. 
Cecal contents of control+vehicle, control+ethanol, DSS+vehicle, DSS+ethanol were 
weighed and submitted to the UIC mass spectrometry core for quantification of the short chain 
fatty acids, acetic acid, propionic acid, and butyric acid. Cecal contents and standards of the three 
short chain fatty acids were derivatized with 3-nitrophenylhydrazine hydrochloride and 3-
ethylcarbodiimide. Samples were analyzed on an AB Sciex Qtrap 5500 coupled to Agilent 
UPLC/HPLC system. Concentrations of cecal content short chain fatty acids were normalized to 
the input weight of the cecal content sample.  
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Blood Alcohol Level Quantification. 
Plasma samples were assayed on an Analox-GL5 machine (Stourbridge, England) to 
detect alcohol according to manufacturer’s guidelines. The apparatus uses the reaction of alcohol 
and oxygen catalyzed by alcohol oxidase to determined alcohol levels. 
Statistics. 
Linear regression, One-way ANOVA followed by Tukey post-hoc test, and Student’s t-
test were performed using GraphPad Prism software (Version 8.1.2). Statistics related to 
sequencing data can be found in preceding Materials and Methods section titled Sequencing Data 
Processing and Analysis. 
Results 
DSS+ethanol Cecal Contents Exhibit Global and Specific Changes in Microbial 
Populations. 
The microbiomes of the mice were examined by 16S rRNA sequencing. Global 
differences in the microbiomes of the mice were assessed by alpha and beta diversity. Different 
alpha diversity assessments can identify the richness and the evenness in a sample. Richness is 
defined as how many different species can be identified in a sample, while evenness determines 
whether there is an equal proportion of bacteria in a sample or does any one type of bacteria 
predominate. Alpha diversity evenness was assessed by two tests, Pielou’s Evenness Index and 
Shannon Index (Figure 15A, B), while alpha diversity richness was assessed by the number of 
observed operational taxonomic units (OTUs) and Faith’s phylogenetic diversity index (Figure 
15C, D). Global changes in alpha diversity were significant for all assessments except for Faith’s 
phylogenetic diversity, which did exhibit a trend for significance. In pairwise assessments of 
evenness, all experimental groups that received DSS+ethanol had significant decreases (or trends 
for significance) in evenness compared to the Control and DSS+vehicle groups. In pairwise 
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assessment of richness, no significance difference was obtained, however, its apparent that all the 
DSS experimental groups exhibited decreased richness relative to the control experimental 
groups.  
Beta diversity assesses differences in microbial composition between different samples. 
This was assessed using both unweighted and weighted UniFrac, which incorporates 
 
 
Figure 15. Combined DSS and Ethanol Administration Decreases Cecal Bacterial 
Alpha Diversity, with Targeted Effects on the Species Evenness. (A) Pielou’s 
evenness, measurement of evenness. (B) Shannon index, measurement of evenness. (C) 
Observed OTUs, measurement of richness. (D) Faith’s phylogenetic diversity. * q < 0.05 
by Kruskal-Wallis pairwise analysis followed by Benjamini & Hochberg correction. 
Samples with horizontal lines above are being used compared to samples with vertical 
lines. 
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phylogenetic distances between samples to determine differences(252). Unweighted UniFrac is a 
qualitative measure taking into account whether a bacterial species is present or absent. 
Weighted UniFrac is a quantitative measure taking into account the abundance of the bacterial 
species. In the PCoA plot output for Weighted UniFrac, we can observe a clear separation 
between the control groups, the DSS+vehicle groups, and the DSS+ethanol groups (Figure 
16A). The Unweighted Unifrac PCoA plot identifies shows that the control groups are clustering 
more closely together, while the DSS groups irrespective of ethanol are clustering more closely 
together (Figure 16B). Despite the closer clustering of the DSS groups in the Unweighted 
UniFrac, there were globally significant differences in both the Weighted and Unweighted 
UniFrac analyses. In addition, during pairwise comparison, all control groups were significantly 
altered compared to the DSS experimental groups (Table 7 and 8). In comparing between the 
DSS experimental groups, there was either significance or a trend for significance between all 
groups using both the weighted and unweighted UniFrac. The only comparison that did not meet 
these criteria was the comparison of the weighted UniFrac result between the DSS+vehicle and 
the DSS+vehicle+L-NIL (q = 0.556). 
 Summary of the bacterial phylum level changes can be seen in Figure 17A. Compared to 
control mice, the DSS groups exhibit an increased abundance of Proteobacteria, with the largest 
increase seen in the DSS+ethanol groups (Figure 17B). The Firmicutes are decreased in the DSS 
groups compared to control groups, with the most significant changes seen in the DSS+ethanol 
groups, irrespective of whether they received the L-NIL and Tungstate treatment (Figure 17C). 
Levels of Bacteroidetes were unchanged (Figure 17D). Verrucomicrobia were increased in the 
DSS and combined ethanol administration groups (Figure 17E), however, we anticipate that this 
effect may be related to a cage effect, related to endogenous bacterial populations. The four 
animals in the DSS+ethanol group with the highest load of Verrucomicrobia, were all housed in 
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Figure 16. Combined DSS and Ethanol Administration Alters β-diversity 
Compared to Other Experimental Groups. (A) Weighted UniFrac. (B) Unweighted 
Unifrac. 
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Table 7. Weighted UniFrac Significance by PERMANOVA with Benjamini-Hochberg 
Correction 
Group 1 Group 2 pseudo-F p-value q-value 
Ctrl+V Ctrl+E 1.06413995 0.365 0.37851852 
Ctrl+V DSS+V 7.1098051 0.001 0.0028 
Ctrl+V DSS+E 8.2439773 0.002 0.00430769 
Ctrl+V DSS+V+L 5.79170171 0.001 0.0028 
Ctrl+V DSS+E+L 13.2497898 0.001 0.0028 
Ctrl+V DSS+V+W 7.33154927 0.001 0.0028 
Ctrl+V DSS+E+W 15.4220541 0.003 0.0056 
Ctrl+E DSS+V 4.58379519 0.006 0.0105 
Ctrl+E DSS+E 5.65522158 0.001 0.0028 
Ctrl+E DSS+V+L 3.79275075 0.012 0.01768421 
Ctrl+E DSS+E+L 9.65103133 0.002 0.00430769 
Ctrl+E DSS+V+W 5.25031447 0.001 0.0028 
Ctrl+E DSS+E+W 10.2677725 0.001 0.0028 
DSS+V DSS+E 1.70381303 0.125 0.14 
DSS+V DSS+V+L 0.7168567 0.556 0.556 
DSS+V DSS+E+L 4.94793215 0.009 0.01482353 
DSS+V DSS+V+W 2.05708161 0.06 0.08 
DSS+V DSS+E+W 7.18746828 0.001 0.0028 
DSS+E DSS+V+L 2.97536786 0.019 0.0266 
DSS+E DSS+E+L 1.34893144 0.219 0.23584615 
DSS+E DSS+V+W 3.35594319 0.012 0.01768421 
DSS+E DSS+E+W 2.32037951 0.085 0.10818182 
DSS+V+L DSS+E+L 6.5408668 0.003 0.0056 
DSS+V+L DSS+V+W 1.86027851 0.105 0.1225 
DSS+V+L DSS+E+W 9.4881251 0.001 0.0028 
DSS+E+L DSS+V+W 6.02937922 0.001 0.0028 
DSS+E+L DSS+E+W 1.88168896 0.091 0.11078261 
DSS+E+W DSS+V+W 8.83009182 0.002 0.00430769 
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Table 8: Unweighted UniFrac Significance by PERMANOVA with Benjamini-Hochberg Correction 
 
Group 1 Group 2 pseudo-F p-value q-value 
Ctrl+V Ctrl+E 0.67353202 0.754 0.754 
Ctrl+V DSS+V 6.180945 0.001 0.00254545 
Ctrl+V DSS+E 5.68654357 0.001 0.00254545 
Ctrl+V DSS+V+L 5.86499438 0.002 0.00373333 
Ctrl+V DSS+E+L 5.40726477 0.001 0.00254545 
Ctrl+V DSS+V+W 5.69089887 0.001 0.00254545 
Ctrl+V DSS+E+W 4.59543277 0.001 0.00254545 
Ctrl+E DSS+V 5.13493122 0.001 0.00254545 
Ctrl+E DSS+E 4.75869829 0.002 0.00373333 
Ctrl+E DSS+V+L 4.73661691 0.002 0.00373333 
Ctrl+E DSS+E+L 4.35830195 0.001 0.00254545 
Ctrl+E DSS+V+W 4.77868705 0.001 0.00254545 
Ctrl+E DSS+E+W 3.792031 0.001 0.00254545 
DSS+V DSS+E 1.30654212 0.122 0.12651852 
DSS+V DSS+V+L 1.45674726 0.047 0.06266667 
DSS+V DSS+E+L 1.33988359 0.064 0.07791304 
DSS+V DSS+V+W 1.72898591 0.002 0.00373333 
DSS+V DSS+E+W 1.91200777 0.062 0.07791304 
DSS+E DSS+V+L 2.0091022 0.001 0.00254545 
DSS+E DSS+E+L 1.29902295 0.074 0.08633333 
DSS+E DSS+V+W 1.61228206 0.033 0.04863158 
DSS+E DSS+E+W 1.77111506 0.086 0.09632 
DSS+V+L DSS+E+L 1.78340984 0.001 0.00254545 
DSS+V+L DSS+V+W 1.85143848 0.003 0.00494118 
DSS+V+L DSS+E+W 2.39889417 0.003 0.00494118 
DSS+E+L DSS+V+W 1.61696638 0.009 0.014 
DSS+E+L DSS+E+W 1.47426941 0.099 0.10661538 
DSS+V+W DSS+E+W 1.98833174 0.043 0.0602 
 
 
 79 
 
 
Figure 17. Combined DSS and Ethanol Administration Alters Bacterial Populations 
at the Phylum Level. (A) Summary of phylum level changes. (B) Proteobacteria. (C) 
Firmicutes. (D) Bacteroidetes. (E) Verrucomicrobia. Values are mean ± SEM. * p<0.05 
by One-Way ANOVA with Tukey post-hoc test. n= 6-8 per group. 
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a single cage, while the other four with the lowest levels of Verrucomicrobia were housed in a 
separate cage. Meanwhile, we can see that for the DSS+vehicle+tungstate mice, there are four 
animals with slight increases of the Verrucomicrobia, these four mice were also housed in a 
single cage. The primary constituents of the Verrucomicrobia in these mice was Akkermansia 
muciniphila (determined by sequencing and qPCR, data not shown), which can be increased in a 
number of inflammatory settings, with studies identifying roles that are pathogenic(253) and 
beneficial(254). Examination of day 0 fecal pellets for A. muciniphila revealed little observable 
difference in the presence of this bacteria in the mice from the various experimental groups (data 
not shown), although studies have noted that the fecal pellet is not the best representative sample 
of the intestinal microbiome(255-257). Furthermore, we do not anticipate that these changes in 
A. muciniphila are due to differences in cecal content sampling since the bacterial load of A. 
muciniphila is roughly consistent on a cage to cage basis.  
 
 
Figure 18. Summary of Family Level Bacterial Changes. n=6-8 per group. 
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Analysis of the microbial constituents at the family level provided more detailed changes 
between the various experimental groups (Figure 18). The results seen for the 
Enterobacteriaceae (Figure 19A) and Lactobacillaceae (Figure 19B) mimic those previously 
observed in Figure 4A and Figure 4B, respectively. Changes were also observed in the 
Ruminococcaceae (Figure 19C) and Lachnospiraceae (Figure 19D) families of bacteria, which 
include a large proportion of bacteria capable of producing butyrate(127). Compared to the 
Control groups, DSS administration groups appeared to increase populations of 
Ruminococcaceae while decreasing Lachnospiraceae. Adding together the reads for the 
Lachnospiraceae and Ruminococcaceae (Figure 19E) displayed an overall decrease in these 
bacteria after DSS administration in comparison to controls which is more pronounced in the 
combination of DSS+ethanol, irrespective of L-NIL and Tungstate treatment. Another family of 
bacteria that we observed to change was that of the Bacteroideaceae (Figure 19F), which, when 
compared to the Control groups, were increased in all the DSS+vehicle groups and significantly 
increased in all the DSS+ethanol groups. Coinfection of Bacteroideaceae and Enterobacteriaceae 
is a common finding in patients with perforated appendicitis(258), meanwhile numerous studies 
have identified that bacteria within these 2 families, chiefly the Bacteroides and Escherichia, 
exhibit synergistic growth which can potentiate disease(259). Furthermore, Bacteroides and 
Escherichia are commonly found in the intestinal mucosa of patients with IBD(260, 261). 
Knowing this, we examined the relationship of Enterobacteriaceae and Bacteroideaceae using 
linear regression and found pronounced correlations of the two bacteria in all DSS receiving 
groups, except the DSS+V+W (Figure 20). Furthermore, the slope of the line for the 
DSS+ethanol mice was nearly equal to 1, indicating that in the setting of DSS+ethanol increases 
in Enterobacteriaceae are met with equal increases in Bacteroidaceae.  
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Figure 19. Combined DSS and Ethanol Administration Alters Bacterial 
Populations at the Family Level. (A) Enterobacteriaceae. (B) Lactobacillaceae. 
(C) Ruminococcaceae. (D) Lachnospiraceae. (E) Lachnospiraceae+ 
Ruminococcaceae. (F) Bacteroidaceae. Values are mean ± SEM. * p<0.05 by One-
Way ANOVA with Tukey post-hoc test. 
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The observed results of the Enterobacteriaceae and Lactobacillaceae from the sequencing data 
were confirmed using qPCR of the Enterobacteriaceae and Lactobacillus (the underlying genus 
of the Lactobacillaceae family; Figure 21). The results of this qPCR were very similar to that 
seen in the sequencing data as well as our prior experiment (Figure 4). 
 To define significant bacterial changes between experimental groups we used the linear 
discriminant analysis Effect Size (LEfSe) method(262). After collapsing the sequencing data to 
the to the family taxonomic level and performing the LEfSe method, we observe that each 
experimental group exhibits some significant increase in particular bacteria (Figure 22).  
 
Figure 20. Correlation Between Enterobacteriaceae and Bacteroidaceae in 
DSS+ethanol Experimental Groups. Lines represent the result of linear regression. 
5 10 15 20 25
-5
0
5
10
15
20
Bacteroidaceae (% of reads)
En
te
ro
ba
ct
er
ia
ce
ae
(%
 o
f r
ea
ds
)
Ctrl+V
Ctrl+E
DSS+V
DSS+E
DSS+V+L
DSS+E+L
DSS+V+W
DSS+E+W
R2 = 0.287
R2 = 0.086
R2 = 0.467
R2 = 0.722
R2 = 0.410
R2 = 0.337
R2 = 0.012
R2 = 0.811
 
Figure 21. qPCR Confirmation of Cecal Content Enterobacteriaceae and 
Lactobacillus Changes. (A) Enterobacteriaceae. (B) Lactobacillus. (C) Lactobacillus: 
Enterobacteriaceae. Values are mean ± SEM. * p<0.05 by One-Way ANOVA with Tukey 
post-hoc test. 
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The Enterobacteriaceae are significantly increased in the DSS+ethanol group, meanwhile 
Lactobacillaceae are most abundant in the control+vehicle group, which has been suggested by 
our prior results. The output of the LEfSe was then plotted on a cladogram, allowing for 
visualization of the different bacterial changes for each experimental group relative to the 
taxonomic level (Figure 23). The center of this graph represents the highest taxonomic level, the 
 
Figure 22. Each Experimental Group Exhibits Differentially Expressed Bacteria at 
the Family Level Identified using the LEfSe Method.  
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kingdom, which in this case is bacteria. Moving outward from the center of the graph to the first 
ring, we observe nine nodes, which represent the nine phyla in our analysis. These nodes then 
branch to give rise to the class, and so on until we reach the outermost set of circles which 
represent the family taxonomic level. We can observe that while some experimental groups are 
enriched in bacteria from the phylum level down to family level, such as the Actinobacteria to 
the Coriobacteriales in the control+vehicle group. In other cases, for example the Firmicutes 
phylum is primarily enriched in the control+vehicle mice, however, examination of the family 
level reveals differential enrichment in of these bacteria in other experimental groups, such as the 
Peptococcaceae in the DSS+ethanol. 
 
 
 
 
Figure 23. Cladogram of Differentially Expressed Bacteria at the Family Level 
Identified using the LEfSe method. The presence of an experimental group color at 
one of the taxonomic levels indicates that at the bacteria within that taxonomic level are 
enriched in that particular experimental group. 
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Nos2 Expression Decrease Associated with Exacerbated Weight Loss. 
Upon seeing that the L-NIL and tungstate treatments induced a decrease in the 
Enterobacteriaceae when administered with DSS+vehicle but not with DSS+ethanol, we 
examined RNA expression of Nos2 in the large IECs of these mice. We found that Nos2 
expression was increased in all the DSS experimental groups, but unlike the changes seen prior 
in Figure 10B, we did not observe that the DSS+E mice had increased levels of Nos2, compared 
to the DSS+vehicle mice (Figure 24A). We also examined Nos2 expression within the cecum 
and found that while all mice receiving DSS had increased Nos2 cecal expression, there were no 
significant differences (Figure 24B). One possibility which may have limited the ability to 
identify the change in Nos2, could be related to the severity of the colitis in this experiment, 
which was increased relative to our previous published experiment(224), as assessed by the day 
7% weight change, colon length, and colon combined histopathology score (Figure 25).  
 
 
 
Figure 24. IEC and Cecum Nos2 RNA Expression Not Different Between DSS 
Groups. (A) IEC RNA expression of Nos2. (B) Cecum RNA expression of Nos2. n=4 
Values are mean ± SEM. * p<0.05 by One-Way ANOVA with Tukey post-hoc test. 
Endogenous control in parentheses. 
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We compared experiments in which we assessed Nos2 IEC expression and found that in the 
setting of increasing weight loss, alcohol administration led to decreased Nos2 expression 
(Figure 26). In comparing all the data points for Nos2 IEC expression and day 7 % weight loss 
from DSS mice on a scatter plot followed by a linear regression, we can that a slight correlation 
exists between weight loss and Nos2 expression, where mice with less weight loss have 
increased Nos2 expression (Figure 26B). There appeared to be threshold of around 10% weight 
 
 
 
Figure 25. Increased Weight Loss Observed in DSS+ethanol Groups. (A) Day 7% 
weight change. (B) Colon length. (C) Combined histopathology score. Values are mean 
± SEM. * p<0.05 by One-Way ANOVA with Tukey post-hoc test. (D). Linear 
regression of cecal Enterobacteriaceae and colon length. 
Ct
rl+
V
Ct
rl+
E
DS
S+
V
DS
S+
E
DS
S+
V+
L
DS
S+
E+
L
DS
S+
V+
W
DS
S+
E+
W
-30
-20
-10
0
10
 D
ay
 7
 %
 W
ei
gh
t C
ha
ng
e
*
* *
*
Ct
rl+
V
Ct
rl+
E
DS
S+
V
DS
S+
E
DS
S+
V+
L
DS
S+
E+
L
DS
S+
V+
W
DS
S+
E+
W
4
6
8
10
C
ol
on
 le
ng
th
 (c
m
)
*
*
*
Ct
rl+
V
Ct
rl+
E
DS
S+
V
DS
S+
E
DS
S+
V+
L
DS
S+
E+
L
DS
S+
V+
W
DS
S+
E+
W
0
5
10
15
20
C
om
bi
ne
d 
H
is
to
pa
th
ol
og
y 
Sc
or
e 
fo
r C
ol
on
 
*
*
4 6 8 10
10-6
10-4
10-2
100
C
ec
al
 
R
Q
 E
nt
er
ob
ac
te
ria
ce
ae
 D
N
A R
2 = 0.4525
 
Ctrl+V
Ctrl+E
DSS+V
DSS+E
DSS+V+L
DSS+E+L
DSS+V+W
DSS+E+W
Colon length (cm)
A B
C D
 88 
 
 
Figure 26. Passing a Weight Loss Threshold Leads to Decreased Expression of Nos2 
Rather than Increased Expression of Nos2. (A) Composite of different experiments in 
which either IECs were assessed for Nos2 RNA expression or swiss rolls were used for 
Nos2 immunostaining. Different groups of experiments are separated by vertical dashed 
line. For fold change determination, all control+vehicle sample Nos2 values were pooled 
together from which was then used the determination of Nos2 fold change. Select 
experiemnts that were used as data are delineated. Nos2 Blot, Nos2 qPCR: Figure 10; 
Nos2 Swiss Roll staining: Figure 11. Values are mean ± SEM. (B) Scatter plot of day 7% 
weight change and Nos2 fold change expression for data presented in (A), with linear 
regression. (C) Scatter plot examining IEC Nos2 expression when weight loss is less than 
10% with linear regression line. (D) Scatter plot examining IEC Nos2 expression when 
weight loss is greater than 10% with linear regression line. n=62. 
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loss where the directionality shifts. Mice that received DSS and had less than 10% weight loss 
had increased expression of Nos2 (Figure 26C), however, weight loss greater than 10% leads to 
decreased expression of Nos2 (Figure 26D). Further corroborating this effect, the mice from 
which the intestinal swiss rolls were produced, exhibited a more moderate weight loss, which 
coincided with the pronounced increase in Nos2 epithelial staining from that experiment (Figure 
11). 
To further determine the role of nitrates in the expansion of the Enterobacteriaceae during 
combined DSS and ethanol administration, we gavaged mice with equal amounts of E. coli that 
were either nitrate reductase proficient (WT) or deficient (DNR) and assessed their growth 
relative to each other (competitive index). This experiment was first attempted with Charles 
River mice, which contain endogenous Enterobacteriaceae(127), and we did not observe any 
viable E. coli (data not shown). The experiment was repeated with Jackson Laboratories mice, 
which do not harbor any endogenous Enterobacteriaceae(127), and we observed viable E. coli on 
day 5 and 6 (Figure 27). On day 7 samples began to no longer exhibit viable E. coli and thus this 
day was excluded from analysis. On day 5, prior to the gavage of either vehicle or ethanol a 
slight competitive advantage appeared to be conferred to the WT bacteria (Figure 27A). On day 
6, the competitive advantage increased for the WT bacteria but no significant difference was 
observed between the DSS+vehicle and DSS+ethanol mice, each of which had received a single 
gavage at this time point when fecal pellets were collected (Figure 27A). In examining the 
samples individually, one from the DSS+vehicle and one from the DSS+ethanol appeared to be 
outliers (shown in dashed lines in Figure 27B). With these outliers removed, the increase in the 
competitive index in the DSS+ethanol group from day 5 to day 6 trended toward significance, 
while no change was observed in DSS+vehicle (Figure Figure 27C, D). In addition, no 
significant change was observed in the competitive index on day 5 or day 6 between the 
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DSS+vehicle and DSS+ethanol, though there was a slight increase in the competitive index for 
DSS+ethanol on day 6 compared to DSS+vehicle (Figure 27C).  
To further elucidate the effects of nitrate production and nitrate utilization in our model, 
we combined both L-NIL and tungstate treatment with either DSS+vehicle or DSS+ethanol. 
Between these two groups, Enterobacteriaceae were unchanged (Figure 28A) while a significant 
decrease in Lactobacillus was observed (Figure 28B). A slight decrease in the 
Lactobacillus:Enterobacteriaceae ratio was observed in the mice receiving the ethanol gavage, 
however, it was not significant (Figure 28C). 
 
 
Figure 27. Slight Advantage Conferred to Nitrate utilization in the Intestine during 
DSS Induced Colitis. (A) Competitive index summary with outliers retained. (B) 
Competitive index individual values with outliers retained. (C) Competitive index 
summary with outliers removed. (D) Competitive index individual values with outliers 
removed. n= 4-5 per group. Two-way ANOVA with Sidak post-hoc test examining 
change between day 5 to day 6. 
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DSS Severely Disrupts Cecal Content SCFAs with Differential Effects Mediated by 
DSS+ethanol. 
Bacterial metabolites, particularly the SCFAs, play an important role in the health of the 
intestine. Prior work has demonstrated the intestinal SCFAs are depleted and intestinal pH is 
disturbed in IBD patients, while alcohol administration in a mouse model has been demonstrated 
to increase intestinal pH(191). Therefore, we examined levels of the cecal contents SCFAs acetic 
acid, propionic acid, and butyric acid (Figure 29). We observe a significant decrease in the total 
SCFAs concentration after DSS administration (Figure 29A). Individual examination of each 
SCFA respective to the experimental groups revealed a similar trend where each individual 
SCFA is decreased after DSS (Figure 29B). In the healthy intestine, acetic acid, propionic acid, 
and butyric acid, exist in ratio of 60:20:20. The ratio of acetic acid in cecal contents 
progressively increases from control+vehicle to DSS+ethanol (Figure 29C). Relative to 
control+vehicle and DSS+vehicle, ethanol administration in control and DSS reduced the ratio of 
propionic acid, although this result was only significant for the control+ethanol group. The ratio 
 
Figure 28. Combined L-NIL and Tungstate Treatment in Setting of DSS+ethanol 
Limits Expansion of Enterobacteriaceae but Lactobacillus Remains Depressed. (A) 
Enterobacteriaceae. (B) Lactobacillus. (C) Lactobacillus: Enterobacteriaceae. Values are 
mean ± SEM. * p<0.05 using Student’s t-test. 
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Figure 29. SCFAs are Depressed during DSS-induced Colitis. (A) Concentration of 
total SCFAs in cecal contents. (B) Concentrations for individual cecal content SCFAs. 
(C) Ratio of individual SCFA to total SCFA. (D) Blood alcohol content. Values are mean 
± SEM. * p<0.05 by One-Way ANOVA with Tukey post-hoc test. 
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of butyric acid was significantly decreased in the DSS groups relative to the control groups. The 
observed increase in the ratio of acetic acid for the mice that received ethanol gavage may be 
related to the presence of alcohol and/or acetaldehyde in the cecum, which are eventually 
metabolized to acetic acid. Interestingly, DSS administration with vehicle gavage is able to 
induce an increase in the ratio of acetic acid compared to the control+vehicle and 
control+ethanol, but only significantly increased with respect to control+vehicle. This suggests 
that colitis itself induces altered metabolism of acetic acid, that becomes further perturbed by 
ethanol. In addition, we observe that the blood alcohol content of mice receiving DSS and the 
ethanol gavage, irrespective of the L-NIL or tungstate treatment, is increased relative to mice 
simply receiving the ethanol gavage (Figure 29D). The increased circulating ethanol may play a 
role in increasing cecal acetic acid by providing sustained amounts of ethanol to the intestine that 
may be used a as substrate for eventual acetic acid production.  
Summary 
Overall, bacterial shifts are noted between each of the DSS groups and the control groups. 
Inhibition of nitrate production by L-NIL and nitrate utilization by Tungstate, prevented the 
overgrowth of Enterobacteriaceae in DSS+vehicle mice, but this effect was not observed in 
DSS+ethanol mice. Ethanol administration after DSS appears to have a very strong effect on 
alpha diversity evenness indicating that certain bacterial populations are being enriched. While 
initially we observed Nos2 expression to be increased in the combination of alcohol and colitis 
relative to colitis alone, this did not appear to be the case in the this set of experiments, likely due 
to an enhanced weight loss response in these mice. This exacerbated body weight may allow for 
sustained LPS signaling within the intestinal epithelium. Examination of tolerance induction 
pathways in the IECs between the DSS+vehicle and DSS+ethanol in this experiment and 
experiments where weight loss was not as severe may further elucidate the observed changes in 
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IEC Nos2 expression. Nitrate reductase proficiency appeared to confer a slight competitive 
advantage in mice experiencing colitis that was slightly improved with ethanol administration. 
Simultaneous inhibition of both nitrate production and nitrate utilization abrogated the effects of 
ethanol on increasing Enterobacteriaceae growth but Lactobacillus remained decreased. SCFAs 
are severely dysregulated in DSS colitis. Ethanol administration appears to contribute to this 
dysregulation by increasing the SCFA ratio of acetic acid. These results suggest that while nitrate 
contributes to intestinal dysbiosis during colitis, ethanol may be inducing alternative pathways 
promoting dysbiosis.  
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CHAPTER SEVEN 
ALCOHOL ATTEUNATES LIVER INFLAMMATION IN SETTING OF COLITIS 
Abstract 
 The portal venous system carries deoxygenated blood from the intestine to the liver. 
Therefore, the liver becomes the point of first contact for any translocated bacteria, bacterial 
components, or bacterial metabolites. Using our mouse model of alcohol and colitis, we 
examined the inflammatory markers and inflammatory signaling pathways in the liver. High 
power magnification of H&E stained sections, revealed a significant increase in mononuclear 
cell counts in liver samples from DSS+ethanol compared to all other groups (p<0.05). Between 
control+ethanol and DSS+vehicle livers, mononuclear cell numbers were unchanged, but both 
groups exhibited significant increases in mononuclear cells compared to control+vehicle livers. 
RNA expression of CXCL1 in DSS+ethanol livers was significantly increased (27-fold) 
compared to control+vehicle and control+ethanol livers. Interestingly, DSS+ethanol CXCL1 
liver expression was significantly lower (2-fold) compared to DSS+vehicle livers. The liver 
RNA expression results of CXCL1 mirrored those at the protein level. Similar results were 
obtained for other inflammatory or inflammatory signaling molecules, except for Lipocalin-2 
(Lcn2). Liver RNA expression of Lcn2 was significantly increased in DSS mice groups 
compared to the control mice, but no difference was observed between DSS+vehicle and 
DSS+ethanol. Western blot analysis of DSS+vehicle liver homogenates revealed increased 
NFkB and STAT1 phosphorylation, while their phosphorylation was undetectable in 
DSS+ethanol liver homogenates. We examined the RNA expression of the inflammatory liver 
markers 24 hours post gavage and found that, compared to three hours post gavage, there was no 
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difference in expression between the DSS+vehicle and DSS+ethanol. These findings suggest that 
while there is an increase in liver mononuclear cells in DSS+ethanol mice, their ability to 
produce inflammatory mediators is compromised shortly after the gavage, due to either direct or 
indirect effects of ethanol. 
Introduction 
 The portal vein accounts for approximately 75% of the total blood flow into the liver with 
the mesenteric veins of the gastrointestinal tract being one of its primary tributaries(263). All the 
nutrients ingested by an organism will eventually flow into this system and become filtered by 
the sinusoids of the liver. To this end, the liver will also be the first point of contact for any 
translocated bacteria and their products. Within the sinusoids, resident macrophages, known as 
Kupffer cells, continuously sample the blood and are poised to initiate a primary inflammatory 
response should they encounter a translocated bacterial organism or its component(264). LPS is 
the most well studied and understood bacterial component in this respect. 
Increased circulating LPS is a common finding in IBD patients(265). IBD patients also 
experience increased liver enlargement and steatosis(266). Altered liver enzymes have been 
noted in IBD patients as well, though they have not been directly linked with IBD disease 
activity(267). Furthermore, IBD patients are also particularly susceptible to development of 
primary sclerosing cholangitis, a disease that leads to fibrosis of the bile ducts(268, 269). These 
liver changes observed in IBD may partially result from the persistent circulating LPS in the 
host.  
Increases in circulating LPS can also be induced with alcohol consumption, acute and 
chronic(188, 270). Meanwhile, various studies have shown that the co-administration of 
antibiotics during alcohol consumption can attenuate the liver inflammatory response induced by 
endotoxin, (214, 270, 271). In addition, since alcohol is primarily metabolized within the liver, 
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we anticipated that this added stressor may exacerbate a liver inflammatory response in our 
mouse model of colitis.  
In our mouse model of colitis, we assessed the liver inflammatory status. We observed a 
decreased inflammatory response in the livers of mice receiving DSS+ethanol compared to 
DSS+vehicle, that coincided with decreased activation of pro-inflammatory transcription factors. 
Therefore, the livers of DSS+ethanol mice exhibited a tolerant phenotype. RNA expression of 
inflammatory genes after a one day recovery from the ethanol or vehicle gavage, were not 
significantly different, indicating a temporal role for alcohol induced liver tolerance in  our 
model. 
Materials and Methods 
Mouse Model of Alcohol and DSS-induced Colitis. 
Male 8-9 week old (∼23–25 g body weight) C57BL/6 mice were obtained from Charles 
River Laboratories (Wilmington, MA). The mouse model used in this study was previously 
described(224). Briefly, mice were randomly assigned to four experimental groups: 
Control+Vehicle (Ctrl+V), Control+Ethanol (Ctrl+E), Dextran sodium sulfate+Vehicle 
(DSS+V), Dextran sodium sulfate+Ethanol (DSS+E). As seen in Figure 2, mice were 
administered either normal drinking water or a 2% (w/v) solution of DSS (36,000-50,000 
molecular weight; MP Biomedicals) ad libitum, starting on day 0 and until day 5. On day 5, DSS 
was stopped and mice received a gavage of either 3g/kg ethanol or water per day until day 7. 
Mice were euthanized three hours after the last gavage. Mice were weighed each day to 
determine percent weight change relative to day 0. After euthanasia livers were removed, a 
portion cut and embedded in optimal cutting temperature media for frozen sectioning and the 
remainder stored at -80° C until processed.  
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For the one day recovery experiment, a similar setup was used as in Figure 2, except that 
instead of sacrificing mice on day seven, mice were allowed to recover from ethanol gavage and 
sacrificed on day eight. Only two groups were generated: DSS+Vehicle+1 Day (DSS+V+1) and 
DSS+Ethanol+1 Day (DSS+E+1). After euthanasia livers were removed and stored at -80° C 
until processed. 
Liver Histology and Oil Red O Staining. 
Livers were fixed in 10% neutral buffered formalin and submitted to AML labs 
(Jacksonville, FL) for processing, embedding, and H&E staining. For mononuclear cell 
quantification of H&E stained liver slides, a single area at 400x was counted by a blinded 
technician.  
Livers embedded in optimal cutting temperature media were cut into 5 um sections in a 
cryostat. Followed by staining at Sections were stained with Oil Red O at the Loyola Histology 
Core. 
Liver RNA Expression. 
RNA was isolated from liver using the RNeasy Mini Kit (Qiagen) according to 
manufacturer’s guidelines. The RNase-free-DNase Set (Qiagen) was used in conjunction with 
the RNA isolation kit to remove genomic DNA. RNA was quantified using a NanoDrop 2000 
spectrophotometer (Thermo Fisher Scientific). cDNA was synthesized using the High Capacity 
cDNA Reverse Transcription Kit (Thermo Fisher Scientific) and run on a Veriti 96-well Fast 
Thermocycler (Life Technologies). 
Expression of targets was assessed by qPCR using TaqMan primer probes and TaqMan 
Fast Advanced Master Mix (Thermo Fisher Scientific). Reactions were performed on a Step One 
Plus qPCR instrument (Applied Biosystems). Endogenous controls for the targets are as listed on  
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the y-axis of the figure. Targets were assessed using the 2^(-ΔCt) method and expressed as fold 
change relative to Control+vehicle. 
Liver Enzyme Linked Immunosorbent Assay. 
CXCL1 ELISA (R&D Systems) of liver homogenates was performed according to 
manufacturer’s instructions. 
Liver Western Blot. 
Thirty mg of liver were homogenized in 1x Cell Lysis Buffer (Cell Signaling Technologies) 
supplemented with 1x Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). 
Protein was quantified using the DC Protein Assay (Bio-Rad). Protein was separated using SDS-
PAGE using Bolt Bis-Tris gels (Thermo Fisher Scientific) and then transferred to a PVDF Membrane 
using a wet transfer method. Membrane was blocked with milk, washed with TBS, then incubated 
overnight with respective antibodies (pNFkB, Cell Signaling Technologies; NFkB Cell Signaling 
Technologies; pSTAT1 Abcam; STAT1 Abcam; β-actin Cell Signaling Technologies). After washing 
with TBST, the membrane was incubated with HRP-linked secondary antibody (Cell Signaling 
Technology) and developed using Western Lightning Plus-ECL, Enhanced Chemiluminescence 
Substrate (Perkin Elmer). Membrane was imaged on a ChemiDoc (Bio-Rad) and densitometry 
analysis performed using ImageLab software (Bio-Rad). Afterwards the blot was stripped using 
Restore Plus Stripping Buffer (Thermo Fisher Scientific) and then reprobed with a different antibody. 
Densitometry analysis examined the ratio of the specific phosphorylated protein to the total 
unphosphorylated protein. 
Statistics: One way ANOVA followed by Tukey post-hoc test was used for significance 
analysis using GraphPad Prism software (Version 8.1.2). For densitometric analysis between the 
DSS+vehicle and the DSS+ethanol, a student’s t-test was performed. 
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Results 
Increased Liver Mononuclear Cells and Lipid Deposition in Livers of DSS+ethanol Mice. 
Bacteria and bacterial products that translocate from the colon, enter into the mesenteric 
circulation and eventually arrive in the liver. Within the liver these translocated elements can 
induce inflammation and accumulation of inflammatory cells. To assess liver inflammation in 
our model, we counted the number of mononuclear cells located around the central vein of H&E 
stained liver sections (Figure 30A). The mean number of mononuclear cells in control+vehicle 
was significantly increased compared to control+ethanol, DSS+vehicle, and DSS+ethanol 
(Figure 30C). No difference in mononuclear cell number was observed between control+ethanol 
and DSS+vehicle, however, DSS+ethanol did exhibit a significant increase compared to these 
two groups. These data suggest that when administered separately, ethanol and DSS induce 
similar mononuclear cell recruitment to the liver, but the combination of ethanol and DSS 
induces an additive effect to enhance the recruitment of mononuclear cells to the liver. 
 
Figure 30. Increased Mononuclear Cells in DSS+ethanol Livers. (A) H&E liver 
sections. Taken at 400x total magnification. Images representative of n=6-8 (B) Liver 
mononuclear cell number. Values are mean ± SEM. * p<0.05 by One-Way ANOVA with 
Tukey post-hoc test. 
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Accumulation of lipids within the liver is a marker of metabolic dysfunction and can be a 
consequence of alcohol consumption. We examined liver fatty deposition using Oil Red O with 
representative images shown in Figure 31. Overall, we observed that the livers of mice receiving 
DSS exhibited increased lipid accumulation with livers from the DSS+ethanol mice having more 
diffuse fat accumulation along with slightly larger droplets. These results indicate that while DSS 
induces liver lipid deposition, the combination of DSS and ethanol further increases that effect.  
 
 
 
 
 
Figure 31. Increased Lipid Deposition in DSS+ethanol Livers. Oil Red O stain of 
frozen liver sections. Taken at 400x total magnification. Representative images of n=6-8 
per group 
 
Ctrl+V Ctrl+E
DSS+V DSS+E
 102 
DSS+ethanol Livers Display Decreased Inflammatory Gene Expression. 
To assess liver inflammation, we examined liver RNA expression of various 
inflammatory markers. We observed that the DSS+vehicle livers had consistent significant 
increases of chemokine (CXC) ligand 1 (CXCL1), tumor necrosis factor alpha, toll-like receptor 
4 (TLR4), and S100 calcium binding protein A9 (S100A9) compared to the liver of control as 
well as DSS+ethanol (Figure 32A-D). The liver RNA expression of these genes in the 
DSS+ethanol group were always significantly lower than the DSS+vehicle group, while also 
often being significantly higher than the control groups. The RNA expression results of CXCL1 
were found to be consistent at the protein level as determined by ELISA (Figure 32E). This 
trend, however, did not persist for Lcn2, which instead was observed to be increased to the same 
degree in both DSS+vehicle and DSS+ethanol (Figure 32F). Upon observing these differential 
effects, we sought to assess whether these changes were associated with changes in activation of 
proinflammatory pathways.  
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Figure 32. Decreased Expression of Inflammatory Genes in DSS+ethanol Livers. (A) 
CXCL1 liver RNA expression. (B) TNF-a liver RNA expression. (C) TLR4 liver RNA 
expression. (D) S100a9 liver RNA expression. (E) CXCL1 liver ELISA. (F) Lcn2 liver 
RNA expression. Values are mean ± SEM. * p<0.05 by One-Way ANOVA with Tukey 
post-hoc test. 
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DSS+ethanol Livers Display Decreased Activation of Proinflammatory Transcription 
Factors. 
Liver homogenates were assessed for activation of pNFkB and STAT1. Control+vehicle 
had no detectable phosphorylated NFkB, while a strong increase in NFkB phosphorylation was 
observed in control+ethanol (Figure 33A). This effect is likely a result of increased endotoxin 
leakage from the intestine reaching the liver. All DSS+vehicle livers, exhibited phosphorylated 
NFkB, meanwhile livers from DSS+ethanol displayed essentially no phosphorylated NFkB. This 
result was significant by densitometric analysis (p<0.05; Figure 33A). The STAT1 
phosphorylation changes mirrored those for NFKB, except that for the control+ethanol livers, we 
did not observe STAT1 phosphorylation (Figure 33B). STAT1 phosphorylation in DSS+vehicle 
was significantly increased relative to DSS+ethanol as determined by densitometry (p<0.05; 
Figure 33B).  
 
 
Figure 33. Decreased Phosphorylation of Transcription Factors in DSS+ethanol Livers. 
(A) Western blot of liver homogenates for pNFkB, NFkB, and b-actin. Underneath is a 
densitometry plot of pNFkB/Total NFkB. (B) Western blot of liver homogenates for pSTAT1 
and STAT1. Underneath is a densitometry plot of pSTAT1/Total STAT1.Values are mean ± 
SEM. * p<0.05 using Student’s t-test examining DSS+vehicle vs DSS+ethanol. 
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These liver expression and activated transcription factor changes observed between the 
DSS+vehicle and DSS+ethanol resemble the phenomena of tolerance, wherein the normal 
response of a cell to a stimulus becomes downregulated after continuous stimulation(272). 
Although some genes, such as Lcn2, are characterized as non-tolerizeable, wherein expression is 
sustained or even increased in situations where a cell/organism exhibits an overall picture of 
tolerance(273). To assess this, we explored the ability of the DSS+ethanol liver to recover 
expression of these inflammatory genes. 
 DSS+ethanol Liver Inflammatory Gene Expression Returns to DSS+vehicle Levels 
24 Hours After Last Gavage.  
After the final gavage of vehicle or ethanol on day seven, mice were allowed an 
additional day to recover and sacrificed on day eight of the experiment. We observed that unlike 
before, TLR4 and S100A9 were expressed to the same degree in the DSS+ethanol livers 
compared to DSS+vehicle livers (Figure 34). Lcn2 was unchanged between the two groups. 
These data seem to indicate that ethanol is playing some role in the mechanism of tolerance that 
we are observing. 
 
Figure 34. Inflammatory Marker Levels in DSS+ethanol Livers are Similar to 
DSS+V Livers 24 Hours After Gavage. (A) TLR4 liver RNA expression. (B) S100a9 
liver RNA expression. (C) Lcn2 liver RNA expression. Values are mean ± SEM. * 
p<0.05 using Student’s t-test examining DSS+vehicle vs DSS+ethanol. 
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Summary 
In our model, we found that livers from DSS+vehicle mice had increased inflammatory 
gene expression and activation of pro-inflammatory transcription factors, compared to the livers 
from the DSS+vehicle mice. In the livers of the DSS-+ethanol mice, inflammatory gene 
expression was greater than the control groups but decreased relative to DSS+vehicle. 
Meanwhile, the phosphorylation of the pro-inflammatory transcription factors was entirely 
absent in the livers of the DSS+ethanol mice.  These results seem to suggest that the livers of the 
DSS+ethanol mice are exhibiting an endotoxin-tolerant phenotype. When sacrificing the mice at 
24 hours after gavage, instead of three hours of gavage, there appeared to be a recovery of the 
inflammatory response in the DSS+ethanol. Further examination of the phosphorylation of 
transcription factors at 24 hours might reveal more information regarding this phenotype. In 
addition, identification of the cell type mediating this response would be of interest. These 
findings suggest that while there is an increase in liver mononuclear cells in DSS+ethanol mice, 
their ability to produce inflammatory mediators is severely compromised in the setting of colitis 
followed by ethanol administration. 
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CHAPTER EIGHT 
DISCUSSION 
Contributions to the Field 
 The overall aims of this work were to first identify from a clinical perspective whether 
there are any defined effects of alcohol consumption in the setting of IBD and then determine 
how alcohol produces these effects in a mouse model. The intersection of IBD and alcohol use 
has been addressed sparingly in the field, despite the plethora of commonalities that encompass 
these two topics. These include effects on the intestinal microbiome, the intestinal epithelium, as 
well as effects on the liver.   
Using a patient database analysis, we determined that patients admitted to a hospital for 
IBD with a documented history of alcohol use, had increased intestinal infections and required 
more antibiotic injections than patients admitted for IBD without a documented history of 
alcohol use. Based on these findings we suspected that alcohol use might further alter the 
intestinal microbiome in IBD, increasing the susceptibility to these infections and therefore 
necessitating antibiotic administration. We explored these potential microbial changes using a 
mouse model of colitis in combination with ethanol administration, where ethanol exacerbates 
the flare period of colitis.  
We observed that the combined colitis and ethanol administration increased the pro-
inflammatory bacteria, Enterobacteriaceae, and decreased the beneficial bacteria, Lactobacillus, 
compared to colitis alone (Figure 35). These changes were associated with increased expression 
of Nos2, which can lead to nitrate production, a favorable energy source for Enterobacteriaceae. 
Blockade of either nitrate production via Nos2 inhibition or bacterial utilization of nitrate, 
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prevented the overgrowth of Enterobacteriaceae during colitis but when ethanol was co-
administered, Enterobacteriaceae growth was only slightly blunted. Furthermore, 16S sequencing 
identified large changes in the microbiome when ethanol is administered during colitis compared 
to colitis alone. These results suggested that ethanol in the setting of colitis may be potentiating 
the growth of the Enterobacteriaceae via other routes. We also identified that the combined 
administration of ethanol and colitis altered liver inflammatory pathways compared to the colitis 
alone, indicating that this model elicits systemic effects not constrained to the intestine.  
Taken together, we have identified ethanol as likely factor in affecting the disease process 
of colitis through ethanol’s effects on the intestinal microbiome. This understanding contributes 
to the pressing need to better understand the effects of ethanol in IBD while also providing 
targetable pathways to prevent colitis flare or limit its severity. 
 
 
 
Figure 35. Summary Figure of Effects from Combined Ethanol and Colitis 
Administration. The effect of ethanol in the setting of colitis contributes to intestinal 
bacterial changes. Nos2 appears to play some role in the changes of the 
Enterobacteriaceae, while ethanol also contributes to decreases in Lactobacillus, 
decreased bacterial diversity, and an altered SCFA ratio. These changes with addition of 
ethanol ability to induce intestinal leakiness, may likely contribute to the profile of 
endotoxin tolerance observed in the livers of mice receiving both the colitis and ethanol 
gavage. 
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Patient Database Analysis Implicates Negative Effects of Alcohol Use in IBD 
Research has shown that IBD patients and alcoholic patients carry an intestinal bacterial 
dysbiosis(116, 192). A dysbiosis is believed to provide pathogens an opportunity to colonize and 
proliferate(274). Indeed, studies have shown IBD patients and alcoholics are at risk for increased 
infections(275, 276). Thus, we anticipated that the combination of alcohol use in a patient with 
IBD would likely further increase intestinal infections, which is exactly what we observe in our 
patient database analysis (Table 6). Furthermore, the patients with a documented history of 
alcohol use (+A) required increased antibiotic injections as well as increased diagnostic 
procedures. Despite these increases, the patients with a documented history of alcohol use (+A) 
had decreased total costs compared to patients without a documented history of alcohol use (-A). 
This can likely be explained by the decrease in surgical procedures (colectomy and small 
intestine resection) observed in the patients with a documented history of alcohol use (+A) 
patients. These patients might be less than ideal candidates for surgery, which is often more 
expensive. In addition, while the median length of stay was unchanged between the  patients 
without a documented history of alcohol use (-A) and those that exhibited a documented history 
of alcohol use (+A), the IQR for the length of stay was increased for the patients which did not 
have a history of documented alcohol use (-A), which may also be related to the increase in 
surgical procedures since surgical patients require longer hospitalization periods post-surgery. 
How this decrease in surgical interventions affects the clinical course of IBD patients with 
alcohol use remains to be further elucidated.  
We would like to note that to be coded for an ICD-9 diagnosis for an alcohol related 
disorder, the patient must have had some history of significant alcohol intake, thus our +A study 
group likely comprises mostly heavy drinkers. Unfortunately, the databases do not contain 
information regarding the amount of alcohol a patient had prior to an admission. Furthermore, 
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the databases do not contain the exact cause of the IBD admission, thus we cannot discern 
whether a patient was admitted for a flare or other complication of IBD. Therefore, the findings 
of this analysis warrant additional research of IBD patients that could provide more detailed 
information beyond what is available through ICD-9 codes. Overall, the results of our patient 
database analysis further support the suggestion that alcohol has some negative impacts on the 
clinical outcomes of patients with IBD(177). 
An interesting hypothesis exists wherein the development of IBD and other 
gastrointestinal disorders is attributed to the westernization of our diet, which no longer provides 
the dietary fibers and nutrients that the healthy gut bacteria rely on for survival(277). Therefore, 
the bacteria that that our intestines have evolved with over the centuries begins to decrease. This 
leads to decreased production of beneficial bacterial metabolites for the intestinal epithelium, 
which then results in intestinal epithelial dysfunction. Thereafter, a vicious cycle can ensue 
wherein the initial disruption of the intestinal microbiome is followed by intestinal inflammation, 
which then promotes the persistence of the altered bacterial populations. As the rates of overall 
alcohol use, binge drinking behavior, and alcohol use disorders continue to increase at staggering 
rates within the United States(278), it’s possible that alcohol consumption may also contribute to 
these intestinal changes and thus contribute in part to the disease process of IBD. 
Enterobacteriaceae and Lactobacillus Changes After Ethanol and Colitis 
In our model, we observed that while colitis induces increases in the Enterobacteriaceae 
and decreases in Lactobacillus, this effect is exacerbated when ethanol is administered in the 
setting of colitis. In addition, colon lengths, an assessment of intestinal inflammatory status, were 
inversely and positively correlated with the abundance of Enterobacteriaceae and Lactoabcillus, 
respectively. Minimal differences were observed in terms of tight junction and mucin staining 
between the DSS+vehicle and DSS+ethanol groups. However, we anticipate that the increased 
 111 
abundance of Enterobacteriaceae, with their infiltrative capacity and endotoxin, are likely 
participating in the exacerbated disease process of combined ethanol and colitis(224). 
Furthermore, since Lactobacillus can limit Enterobacteriaceae growth (102-106) and beneficial 
effects are often associated with Lactobacillus administration in various disease states(279), their 
sharp decrease in DSS+ethanol may explain the further potentiation of the flare compared to 
DSS+vehicle.  
Previous studies have identified that IBD patients(115, 132) and individuals with alcohol 
use(189, 190) both exhibit intestinal bacterial perturbations, with notable increases in 
Enterobacteriaceae, and decreases in Lactoabcillus. Changes mirroring these have also been 
identified in the oral microbiome of patients with ethanol use, specifically that alcohol 
consumption decrease oral Lactoabcillus and increases Proteobacteria(196). Based on these 
previous studies, we anticipated that the interaction of ethanol and colitis would exacerbate the 
bacterial changes, which is exactly what we observed. The mechanism by which colitis and 
ethanol contribute to this change may be related to the changes in the intestinal metabolites 
which favor the growth of the Enterobacteriaceae over the Lactobacillus. These substrates 
include oxygen, nitrate, formate, and trimethylamine-N-oxide (TMAO) (127, 242, 280). There 
are also select strains of intestinally derived E. coli  that oxidize ethanol to acetaldehyde under 
conditions similar to that found within the intestine(205). Meanwhile the Lactobacillus primarily 
utilize fermentative pathways to generate energy(281), although select strains have been shown 
to use oxygen or have genetic components that may allow them to use oxygen(282). These 
substrates available for Enterobacteriaceae use are much more energetically than those available 
to the Lactobacillus(155). 
Another possibility is that a colitis flare and ethanol lead to increased oxidative stress 
within the intestine, which the Enterobacteriaceae are adapted to tolerate(149-153) while in 
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general the Lactobacillus are limited in their capacity to withstand oxidative stress(283, 284). 
Alcohol metabolism may contribute to this oxidative environment, via the cytochrome P450 
2E1metaboclic pathway, which generates hydrogen peroxide(285) or via the production of 
acetaldehyde, which can generate harmful adducts (207). Since the metabolism of alcohol to 
acetaldehyde and then acetate increases the cellular pool of NADH by two molecules, cells that 
metabolize ethanol  have increased resources to apply towards oxidative metabolism, which can 
increase reactive oxygen species generation(286). Importantly, the alteration in nutrients and 
increased oxidative environment of the intestine during colitis flare are not mutually exclusive, 
since an increased oxidative environment can also facilitate the production of substrates 
favorable to Enterobacteriaceae growth. 
Ethanol may also induce bacterial alterations via changes in intestinal pH. Maintenance 
of intestinal pH is crucial for the optimization of SCFA production and the survival of bacteria 
that produce the SCFAs(87, 109). One study identified a number of relevant changes in a mouse 
model fed an alcohol diet. Shortly after beginning the alcohol diet, mice developed increased 
fecal pH compared to pair-fed controls(191). The increase in fecal pH persisted until the 
experiment ended at eight weeks. In addition, a subset of alcohol fed mice were given a daily 
gavage of Lactobacillus rhamnosus GG which significantly reduced the fecal pH compared to 
mice only receiving the alcohol diet. Furthermore, these fecal pH changes coincided with 
relevant changes in the intestinal microbiome as assessed by sequencing. These changes included 
increased abundance of Proteobacteria and decreased Lactobacillus in the alcohol fed group, 
while the alcohol fed mice that also received L. rhamnosus GG had decreased Proteobacteria 
and, as would be expected, increased Lactobacillus. 
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Nos2 and Reactive Oxygen Enzyme Changes 
Due to the observed increase in the Enterobacteriaceae from the DSS+ethanol group, we 
anticipated that there must be some change in intestinal metabolites in our model. A prior study 
using the model of DSS-induced colitis, found that nitrate was of particular importance to the 
overgrowth of Enterobacteriaceae during colitis, with intestinally derived Nos2 being the major 
contributor to this effect(242). Therefore, we explored the possibility that the administration of 
ethanol in the setting of colitis may further potentiate the expression of Nos2. 
Other studies have identified that ethanol has a potentiating effect on Nos2 activation and 
production of nitric oxide by treating Caco-2 cells with ethanol(287). Meanwhile, in vivo studies 
have demonstrated differential effects of ethanol on Nos2 expression and activation, some 
showing a potentiating effect and others showing an inhibitory effect(288). Ethanol can also 
interact directly the nitric oxide metabolite, peroxynitrite, yielding ethyl nitrite(289). Ethyl nitrite 
exhibits a longer half-life than that of nitric oxide and also acts as nitric oxide donor(290). 
Therefore, the ethyl nitrite may prolong the persistence of nitric oxide and the generation of 
nitrate within the intestine. 
In our model, we observed that post DSS, ethanol was able to increase Nos2 expression. 
This expression was localized to the intestinal epithelium. We also observed upregulation of the 
reactive oxygen producing enzyme Duox2 after DSS with no additional effect on expression 
when ethanol was added. The end products generated by these enzymes are necessary precursors 
to generate nitrate. Reactive oxygen can also be generated by other pathways, such as Nox 
enzymes. We examined the most highly expressed Nox enzyme in the intestinal epithelium, 
Nox1, and found no difference in expression between DSS administered mice and controls. 
Another source of reactive oxygen could be the invading neutrophils and their expression of 
Nox2, another Nox isoenzyme, however, we did not examine Nox2 expression in our model. 
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Although Nox1 expression was unchanged, examining the localization of the cytosolic subunits 
(Noxa1 and Noxo1) would indicate whether some experimental groups exhibit more Nox1 activity 
compared to others, since active Nox1 would have cytosolic subunits in close proximity(291). In 
contrast to this Nos2, once expressed is constitutively active(230).  
Inhibition of Nitrate Production and Utilization 
Having observed the relationship between the increase in Enterobacteriaceae and Nos2 
expression, we decided to inhibit Nos2 activity and nitrate utilization and examine its 
downstream effects on Enterobacteriaceae in our model. We employed the specific Nos2 
inhibitor, L-NIL, and the nitrate reductase inhibitor, tungstate. We observed as in previously 
published studies that L-NIL and tungstate were able to reduce the overgrowth of 
Enterobacteriaceae after colitis. However, when these treatments were applied to mice receiving 
the ethanol post DSS, the inhibition of Enterobacteriaceae growth was no longer observed. One 
explanation for this effect is that when L-NIL and tungstate are administered and the 
Enterobacteriaceae can no longer use nitrates, their metabolism may shift to utilize an alternative 
energy source since E. coli are flexible in their metabolism and can use a variety of substrates to 
produce energy.  
Select strains of intestinally derived E. coli can generate ATP via the conversion of 
ethanol to acetaldehyde(205). However, the more commonly used E. coli metabolic pathway is 
alcoholic fermentation, which involves the reverse reaction, converting acetaldehyde to 
ethanol(292-294). The increased abundance of acetaldehyde within the large intestine after 
alcohol consumption(203, 204), therefore may provide yet another source of energy yielding 
substrates to the Enterobacteriaceae that would not be inhibited by administration of either of our 
treatments. In addition, our experiments using the nitrate reductase deficient E. coli, suggest that 
in either DSS+vehicle or DSS+ethanol, nitrate may not be as advantageous to growth, which is 
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in contrast to other studies(242, 247). However, the observed decrease in colonization of these 
mice gavaged with the WT or ΔNR might explain the limited changes observed in this 
experiment. The decrease colonization may be due to the niche which the bacteria are trying to 
fill, is already being occupied by another bacterium. 
Another possibility for the persistence of Enterobacteriaceae in the mice receiving 
DSS+ethanol despite the treatments, may be related to differential drinking of the water in the 
mice. As the mice were co-housed, accurate measuring of volume intake per mouse was not a 
possibility. Future experiments may consider single housing mice, which would have the added 
benefit of limiting cage effects, using an intraperitoneal injection or an oral gavage of the 
treatment, and the use of metabolic cages, which would also allow us to measure other elements 
like food consumption and energy expenditure of the mice. We may also consider a different 
treatment regimen that would allow longer treatment with L-NIL and tungstate prior to initiating 
our experimental protocol. Lastly, effects of whether mice receive enough treatment can be 
mitigated by using mice that are deficient for Nos2. Care would need to taken to select strains 
that exhibit endogenous Enterobacteriaceae, or either ensure colonization of the Nos2 deficient 
mice via other means.  
However, upon examining the sequencing data results, we can observe that there are 
appreciable differences between the three groups of DSS+ethanol, DSS+ethanol+L-NIL, and 
DSS+ethanol+tungstate. Trends for significance can be observed in the weighted and 
unweighted UniFrac analysis. These trends persist even between the DSS+ethanol+L-NIL and 
DSS+ethanol+tungstate, suggesting that in each of these groups the different treatments are 
inducing differential effects on the bacterial populations. Further confirmation of this can be 
observed when examining the results of the LefSe, which identifies differentially abundant 
bacteria in each of the three groups.  
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The observed decrease in Nos2 in the L-NIL and tungstate treatments may be related to 
the severity of the colitis as determined by the weight loss observed in these experiments 
compared to that observed in prior experiments (Figure 6.14). This severity of the colitis in our 
model can also be observed by the histopathology score, which is much higher than in our 
previous publication(224). The mechanism for the observed decrease in Nos2 could be due to an 
overabundance of LPS signaling, inducing an endotoxin tolerant phenotype. Various epithelial 
cells are capable of expressing a tolerant phenotype to successive administrations of LPS, 
including IECs(295), intrahepatic biliary epithelial cells(296), and alveolar epithelial cells(297). 
Furthermore, decreased expression of Nos2 has been previously linked to endotoxin tolerance in 
IECs(298) and macrophages(299).  
While endogenous tolerance of IECs might constitute one mechanism of this tolerance, 
tolerance of the immune cell populations present within the large intestine may trickle down to 
affect IEC expression of Nos2. This may occur via altered secretion of tumor necrosis factor α, 
interleukin 1β, and interferon γ(231), which are potent activators of Nos2 expression. In fact in 
the DSS-colitis model, antibody mediated depletion of interferon γ and tumor necrosis factor α, 
was able to reduce increases in Nos2 expression(300). Macrophages can stimulate interferon γ 
secretion from T cells and NK cells, while endotoxin tolerant macrophages are attenuated in this 
capacity(301). It’s possible that in our experiment a similar situation is occurring leading to 
depression of Nos2 expression in IECs. 
When L-NIL and tungstate were used in conjunction to treat mice receiving DSS there 
was no observed increase of Enterobacteriaceae due to ethanol gavage compared to vehicle 
gavage. However, the effect of ethanol on Lactobacillus persisted. This observed effect seems to 
suggest that ethanol mediates direct effects on Lactobacillus. With regard to Enterobacteriaceae 
it’s possible that the L-NIL and tungstate may somehow act synergistically to reduce any effects 
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ethanol may confer to the Enterobacteriaceae. Alternatively, due to the small sample size, we 
may have been unable to observe the effects of ethanol on the Enterobacteriaceae.  
SCFAs are essential to the health of the intestine. We observed that the total 
concentration of cecal SCFAs are decreased after DSS colitis, while the ratios of these SCFAs 
are also disturbed when comparing between the four groups (control+vehicle, control+ethanol, 
DSS+vehicle, DSS+ethanol). Two research studies on murine models fed alcohol diets, 
identified that alcohol can induce increases in acetic acid, and decreases in propionic acid, and 
butyric acid(302, 303). In our model, the cecal SCFAs between the control+vehicle and 
control+ethanol largely recapitulate these findings, though the effect on butyric acid was not 
observed in our model. This may be due to the more acute nature of our ethanol regimen than 
those from the other studies. The DSS experimental groups, compared to control groups, 
exhibited an overall decrease in the total concentration of SCFAs, while also exhibiting 
decreases in each individual SCFA. Examination of the SCFA revealed that on their own, 
ethanol or DSS increases the SCFA ratio of acetic acid, while the combination of DSS+ethanol 
leads to an even higher ratio of acetic acid. The increases of acetic acid in the ethanol 
administered groups is likely due to the metabolism of ethanol to acetate.  
The observed shifts in the total SCFA and SCFA ratios, may also have a differential 
effect on the inhibition of pro-inflammatory bacteria. Butyrate is the primary energy source of 
IECs, as well as serves as modulator of immune function. Butyrate has also been determined to 
be a ligand that activates the transcription factor peroxisome proliferator-activated receptor γ, 
which can inhibit the expression of Nos2(127, 304). Inhibition of Enterobacteriaceae growth has 
been ascribed to the SCFAs acetic acid and butyric acid(111), as well as propionic acid(305). 
Therefore, the sharp decrease in these SCFAs and the alteration of the ratios seen in DSS 
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administered mice likely also play a part in the overgrowth of the Enterobacteriaceae observed in 
our model.  
DSS+ethanol Induced Liver Endotoxin Tolerance 
In our model, we observed that the livers of control+ethanol and DSS+vehicle had 
similarly increased numbers of mononuclear cells compared to livers of control+vehicle. 
DSS+ethanol livers exhibited the most mononuclear cells of all experimental groups. This initial 
finding seemed to suggest that the livers of the DSS+ethanol mice may be experiencing more 
inflammation. However, RNA expression of inflammatory genes revealed that the DSS+vehicle 
livers had the highest expression, the control groups exhibited minimal expression, and the 
DSS+ethanol had an intermediate expression. This seemed to indicate that the livers of 
DSS+ethanol mice were exhibiting a tolerant phenotype. We also observed sustained expression 
of Lcn2 in the DSS experimental groups, which is non-tolerizeable. Observation of increased 
activation of proinflammatory transcription factors in DSS+vehicle mice livers, while decreased 
activation is observed in the DSS+ethanol mice livers, further supporting the conclusion that the 
DSS+ethanol livers are tolerant. 
The induction of tolerance in part relies on the increased expression of IRAK-M, which 
has been identified as a negative regulator of TLR signaling(306). In contrast, the persistent 
expression of Lcn2 was described in kidney fibroblasts to occur via a biphasic mechanism 
wherein LPS activates TLR4, leading to early phase activation of c-Jun, followed by late phase 
and sustained activation of C/EBPδ(307). 
Within the acute setting of alcohol intake, temporal regulation governs the inflammatory 
response of Kupffer cells. LPS treatment of Kupffer cells isolated from rats two hours after 
alcohol administration exhibit a decreased inflammatory response, while Kupffer isolated 24 
hours after alcohol administration exhibit an increased inflammatory response(214). To examine 
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whether a similar effect occurs in our model, we assessed liver inflammatory gene expression 24 
hours after the last ethanol gavage, instead of the usual three hours. We found that the 
inflammatory gene expression in the liver did not differ between the mice that received ethanol 
or a vehicle 24 hours prior to sacrifice. In addition, there may have even been an increase in the 
expression of these genes in the DSS+ethanol+1 mouse livers, however, this experiment will 
need to be repeated in order to sufficiently determine this effect. 
Inflammation of the liver and mononuclear cell infiltrate has been previously observed in 
various mouse models of colitis, including DSS(308). When GF mice were administered DSS, 
they developed colitis but the numbers of liver mononuclear cells were unchanged from that of 
germ free mice receiving water(308). Other effects of DSS administration include alteration of 
liver metabolism leading to increased lipoprotein lipase(309) and increased circulating 
lipids(310), alanine aminotransferase, and aspartate aminotransferase(311).  
The fact that IBD patients have increased circulating levels of endotoxin indicates that 
their livers are exposed to more than normal levels of endotoxin and thus might be stressed(265). 
In this regard, studies have found that some IBD patients have increased hepatic steatosis, liver 
enlargement(266), and elevated liver enzymes(267). The addition of alcohol in our model could 
lead to indirect effects on the liver by increasing the intestinal permeability, increasing the 
abundance of endotoxin expressing bacteria, and/or directly by the added stress on the liver to 
metabolize circulating alcohol. The presence of increased circulating alcohol relative to the 
control+ethanol mice, seems to suggest that there is some dysfunction of alcohol metabolism in 
the DSS+ethanol mice that is still observed when L-NIL or tungstate is administered. 
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